Recombinantly-Modified Adeno-Associated Virus Helper Vectors and Their Use to Improve the Packaging Efficiency of Recombinantly-Modified

Adeno-Associated Virus

FIELD OF THE INVENTION:

[0001] The present invention is directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV) and their use to improve the packaging efficiency of such rAAV. The present invention is particularly directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that have been further modified to replace (or augment) the P5 and/or P40 promoter sequences that are natively associated with the Rep proteins encoded by such rAAV with AAV P5 and/or P40 promoters that are associated with the Rep proteins of an rAAV of different serotype. The use of such substitute or additional promoter sequences causes increased production of recombinantly-modified adeno-associated virus.

REFERENCE TO SEQUENCE LISTING

[0002] This application includes one or more Sequence Listings pursuant to 37 C.F.R. 1.821 et seq., which are disclosed in computer-readable media (file name: 2650- 0004US_ST25.txt, created on July 15, 2019, and having a size of 84,101 bytes), which file is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION:

I. Adeno-Associated Virus (AAV)

[0003] Adeno-Associated Virus (AAV) is a small, naturally-occurring, non- pathogenic virus belonging to the Dependovirus genus of the Parvoviridae (Balakrishnan, B. et al. (2014)“ Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy ,” Curr. Gene Ther. 14(2):86-100; Zinn, E. et al. (2014) ‘ del· lo-A ssociated Virus: Fit To Serve f Curr. Opin. Virol. 0:90-97). Despite not causing disease, AAV is known to be able to infect humans and other primates and is prevalent in human populations (Johnson, F.B. et al. (1972)“ Immunological Reactivity of Antisera Prepared Against the Sodium Dodecyl Sulfate-Treated Structural Polypeptides of Adenovirus-Associated Virus,” J. Virol. 9(6): 1017-1026). AAV infect a broad range of different cell types ( e.g. , cells of the central nervous system, heart, kidney, liver, lung, pancreas, retinal pigment epithelium or photoreceptor cells, or skeletal muscle cells). Twelve serotypes of the virus (e.g, AAV2, AAV5, AAV6, etc.), exhibiting different tissue infection capabilities (“tropisms”), have been identified (Colella, P. et al. (2018)“Emerging Issues in AAV-Mediated In Vivo Gene Therapy ,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Hocquemiller, M. et al. (2016)“ Adeno - Associated Virus-Based Gene Therapy for CNS Diseases,” Hum. Gene Ther. 27(7):478- 496; Lisowski, L. et al. (2015) “ Adeno-Associated Virus Serotypes For Gene Therapeutics ,” 24:59-67).

[0004] AAV is a single-stranded DNA virus that is composed of approximately 4,800 nucleotides. The viral genome may be described as having a 5’ half and a 3’ half which together comprise the genes that encode the virus’ proteins (Figure 1). The 5’ half of the AAV genome comprises the AAV rep gene, which, through the use of multiple reading frames, staggered initiating promoters (P5, P19 and P40) and alternate splicing, encodes four non- structural Rep proteins (Rep40, Rep52, Rep68 and Rep78) that are required for viral transcription control and replication and for the packaging of viral genomes into the viral capsule (Lackner, D.F. et al. (2002)“ Studies of the Mechanism of Transactivation of the Adeno-Associated Virus pl9 Promoter by Rep Protein ,” J. Virol. 76(16):8225-8235). In the presence of viral proteins (such as Ad proteins), the P5 promoter becomes activated and mediates the transcription of the Rep68 and Rep78 proteins, which are involved in transcriptional control, in latency, in rescue, and in viral DNA replication and thus function as master controllers of the AAV life cycle (Murphy, M. et al. (2007)“ Adeno-Associated Virus Type 2 p5 Promoter: a Rep-Regulated DNA Switch Element Functioning in Transcription, Replication, and Site-Specific Integration ,” J. Virol. 81(8):3721-3730). Expression of the Rep68 and Rep78 proteins activates the P19 promoter, which is responsible for the transcription of the Rep40 and Rep52 proteins (Lackner, D.F. et al. (2002) “ Studies of the Mechanism of Transactivation of the Adeno-Associated Virus p!9 Promoter by Rep Protein ,” J. Virol. 76(16):8225-8235; Ogasawara, Y. et a!. (1998)“The Use of Heterologous Promoters for Adeno-Associated Virus (AAV) Protein Expression in AAV Vector Production ,” Microbiol. Immunol. 42(3): 177-185). The 3’ half the AAV genome comprises the AAV capsid gene (cap), which encodes three capsid proteins (VP): VP1, VP2 and VP3. The three capsid proteins are translated from a single mRNA transcript that is controlled by a single promoter (P40 in case of AAV2). The 3’ half of the AAV genome also comprises the AAP gene, which encodes the AAV assembly-activating protein (AAP). Sixty VP monomers (comprising approximately 5 copies of VP1, 5 copies of VP2, and 50 copies of VP3) self-assemble around the AAV genome to form the icosahedral protein shell (capsid) of the mature viral particle (Biining, H. et al. (2019) “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” Mol. Ther. Meth. Clin. Devel. 12P248-P265; Van Vliet K.M. et al. (2008) The Role of the Adeno-Associated Virus Capsid in Gene Transfer. In: DRUG DELIVERY SYSTEMS, Jain, K.K. (eds.), Meth. Molec. Biol. 437:51-91). The AAV AAP protein is believed to be required for stabilizing and transporting newly produced VP proteins from the cytoplasm into the cell nucleus. The 3’ half of the AAV genome also comprises the AAV X gene, which is believed to encode a protein that supports genome replication (Colella, P. et al. (2018)“Emerging Issues in AAV-Mediated In Vivo Gene Therapy ,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Biining, H. et al. (2019)“ Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors ,” Mol. Ther. Meth. Clin. Devel. 12P248-P265; Cao, M. et al. (2014)“ The X Gene Of Adeno- Associated Virus 2 (AAV2 ) Is Involved In Viral DNA Replication ,” PLoS ONE 9, el04596: l-10).

[0005] The above-described AAV gene-coding sequences are flanked by two AAV- specific palindromic inverted terminal repeated sequences (ITR) of 145 nucleotides (Balakrishnan, B. et al. (2014)“ Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy,” Curr. Gene Ther. 14(2):86-100; Colella, P. et al. (2018)“Emerging Issues in AAV-Mediated In Vivo Gene Therapy,” Molec. Ther. Meth. Clin. Develop. 8:87-104).

[0006] AAV is an inherently defective virus, lacking the capacity to perform at least two critical functions: the ability to initiate the synthesis of viral-specific products and the ability to assemble such products to form the icosahedral protein shell (capsid) of the mature infectious viral particle. It thus requires a co-infecting“helper” virus, such as adenovirus (Ad), herpes simplex virus (HSV), cytomegalovirus (CMV), vaccinia virus or human papillomavirus to provide the viral-associated (VA) RNA that is not encoded by the genes of the AAV genome. Such VA RNA is not translated, but plays a role in regulating the translation of other viral genes. Similarly, the AAV genome does not include genes that encode the viral proteins Ela, Elb, E2a, and E4; thus, these proteins must also be provided by a co-infecting“helper” virus. The Ela protein greatly stimulate viral gene transcription during the productive infection. The Elb protein block apoptosis in adenovirus-infected cells, and thus allow productive infection to proceed. The E2a protein plays a role in the elongation phase of viral strand displacement replication by unwinding the template and enhancing the initiation of transcription. The E4 protein has been shown to affect transgene persistence, vector toxicity and immunogenicity (see, Grieger, J.C. et al. (2012)“ Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications ,” Meth. Enzymol. 507:229- 254; Dyson, N. et al. (1992)“ Adenovirus El A Targets Key Regulators Of Cell Proliferation,” Cane. Surv. 12: 161-195; Jones N.C. (1990)“ Transformation By The Human Adenoviruses ,” Semin. Cancer Biol. l(6):425-435; Ben-Israel, H. et al. (2002) “ Adenovirus and Cell Cycle Control ,” Front. Biosci. 7:dl369-dl395; Hoeben, R.C. et al. (2013)“ Adenovirus DNA Replication ,” Cold Spring Harb. Perspect. Biol. 5:a013003 (pages 1-11); Berk, A.J. (2013)“ Adenoviridae : The Viruses And Their Replication, In: FIELDS VIROLOGY, 6 ^th Edition (Knipe, D.M. et al., Eds.), Vol. 2., Lippincott Williams & Wilkins, Philadelphia, pages 1704-1731; Weitzman, M.D. (2005)“Functions Of The Adenovirus E4 Proteins And Their Impact On Viral Vectors ,” Front. Biosci. 10: 1106- 1117).

[0007] AAV viruses infect both dividing and non-dividing cells, and persist as circular episomal molecules or can be integrated into the DNA of a host cell at specific chromosomic loci (Adeno-Associated Virus Integration Sites or AAVS) (Duan, D. (2016)“ Systemic Delivery Of Adeno-Associated Viral Vectors ,” Curr. Opin. Virol. 21 : 16-25; Grieger, J.C. et al. (2012) “ Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications ,” Meth. Enzymol. 507:229-254). AAV remains latent in such infected cells unless a helper virus is present to provide the functions needed for AAV replication and maturation. II. rAAV and Their Use in Gene Therapy

[0008] In light of AAV’s properties, recombinantly-modified versions of AAV (rAAV) have found substantial utility as vectors for gene therapy (see, Naso, M.F. et al. (2017)“ Adeno-Associated Virus (AAV) as a Vector for Gene Therapy ,” BioDrugs 31 :317-334; Berns, K. I. et al. (2017) 'AAV: An Overview of Unanswered Questions ,” Human Gene Ther. 28(4):308-313; Berry, G.E. et al. (2016)“ Cellular Transduction Mechanisms Of Adeno-Associated Viral Vectors ,” Curr. Opin. Virol. 21 :54-60; Blessing, D. et al. (2016)“ Adeno-Associated Virus And Lentivirus Vectors: A Refined Toolkit For The Central Nervous System,” 21 :61-66; Santiago-Ortiz, J.L. (2016) “ Adeno-Associated Virus (AAV) Vectors in Cancer Gene Therapy ,” J. Control Release 240:287-301; Salganik, M. et al. (2015)“ Adeno-Associated Virus As A Mammalian DNA Vector ,” Microbiol. Spectr. 3(4): 1-32; Hocquemiller, M. et al. (2016)“ Adeno- Associated Virus-Based Gene Therapy for CNS Diseases,” Hum. Gene Ther. 27(7):478- 496; Lykken, E.A. et al. (2018) "Recent Progress And Considerations For AAV Gene Therapies Targeting The Central Nervous System ,” J. Neurodevelop. Dis. 10: 16: 1-10; Biining, H. et al. (2019)“ Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; During, M.J. et al. (1998)“ In Vivo Expression Of Therapeutic Human Genes For Dopamine Production In The Caudates Of MPTP-Treated Monkeys Using An AAV Vector,” Gene The. 5:820-827; Grieger, J.C. et al. (2012)“ Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications,” Meth. Enzymol. 507:229-254; Kotterman, M.A. et al. (2014) “ Engineering Adeno-Associated Viruses For Clinical Gene Therapy,” Nat. Rev. Genet. 15(7):445-451; Kwon, I. et al. (2007)“ Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer ,” Pharm. Res. 25(3):489-499; US Patents No.: 10,266,845; 10,081,659; 9,890,396; 9,840,719; 9,839,696; 9,834,789; 9,803,218; 9,783,825; 9,777,291; 9,540,659; 9,527,904; 8,236,557; 7,972,593 and 7,943,374).

[0009] rAAV are typically produced using circular plasmids (“rAAV plasmid vector”). The AAV rep and cap genes are typically deleted from such constructs and replaced with a promoter, a b-globin intron, a cloning site into which a therapeutic gene of choice (transgene) has been inserted, and a poly-adenylation (“poly A”) site. The inverted terminal repeated sequences (ITR) of the rAAV are, however, retained, so that the transgene expression cassette of the rAAV plasmid vector is flanked by AAV ITR sequences (Colella, P. et al. (2018)“Emerging Issues in AAV-Mediated In Vivo Gene Therapy ,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Biining, H. et al. (2019) “Capsid Modifications for Targeting and Improving the Efficacy ofAA V Vectors ,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265). Thus, in the 5’ to 3’ direction, the rAAV comprises a 5’ ITR, the transgene expression cassette of the rAAV, and a 3’ ITR.

[0010] rAAV have been used to deliver a transgene to patients suffering from any of a multitude of genetic diseases ( e.g ., hereditary lipoprotein lipase deficiency (LPLD), Leber’s congenital amaurosis (LCA), aromatic L-amino acid decarboxylase deficiency (AADC), choroideremia and hemophilia), and have utility in new clinical modalities, such as in interfering RNA (RNAi) therapy and gene-modifying strategies such as Crispr/Cas9 (US Patents No. 8,697,359, 10,000,772, 10,113,167, 10,227,611; Lino,

C.A. etal. (2018)“Delivering CRISPR: A Review Of The Challenges And Approaches ,” Drug Deliv. 25(1): 1234-1237; Ferreira, V. et al. (2014)“Immune Responses To AAV- Vectors, The Glybera Example From Bench To Bedside" Front. Immunol. 5(82): 1-15), Biining, H. el al. (2019)“ Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors ,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Rastall,

D.P.W. (2017)“ Current and Future Treatments for Lysosomal Storage Disorders ,” Curr. Treat Options Neurol. 19(12):45; Kay, M. et al. (2017)“ Future Of rAAV Gene Therapy: Platform For RNAi, Gene Editing And Beyond ,” Human Gene Ther. 28:361- 372); Berns, K. I. etal. (2017)“AAV: An Overview of Unanswered Questions ,” Human Gene Ther. 28(4):308-313). More than 150 clinical trials involving rAAV have been instituted (Biining, H. etal. (2019)“Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors ,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Clement, N. et al. (2016)“ Manufacturing Of Recombinant Adeno-Associated Viral Vectors For Clinical Trials ,” Meth. Clin. Develop. 3: 16002: 1-7). The most commonly used AAV serotype for such recombinantly-modified AAV is AAV2, which is capable of infecting cells of the central nervous system, kidney, retinal pigment epithelium and photoreceptor cells. AAV serotype is AAV9, which infects muscle cells, also has been widely used (Duan, D. (2016)“Systemic Delivery Of Adeno-Associated Viral Vectors ,” Curr. Opin. Virol. 21 :16-25). AAV serotypes are described in US Patents No. 10,301,650; 10,266,846; 10,265,417; 10,214,785; 10,214,566; 10,202,657; 10,046,016; 9,884,071; 9,856,539; 9,737,618; 9,677,089; 9,458,517; 9,457,103; 9,441,244; 9,193,956; 8,846,389; 8,507,267; 7,906,111; 7,479,554; 7,186,552; 7,105,345; 6,984,517; 6,962,815; and 6,733,757.

III. Methods of rAAV Production

[0011] rAAV containing a desired transgene expression cassette are typically produced by human cells (such as HEK293) grown in suspension. Since, as described above, rAAV are defective viruses, additional functions must be provided in order to replicate and package rAAV.

[0012] rAAV can be produced by transiently transfecting cells with an rAAV plasmid vector and a second plasmid vector that comprises an AAV helper function-providing polynucleotide that provides the Rep52 and Rep78 genes that are required for vector transcription control and replication, and for the packaging of viral genomes into the viral capsule (Rep40 and Rep68 are not required for rAAV production) and the cap genes that were excised from the AAV in order to produce the rAAV. The second plasmid vector may additionally comprise a non-AAV helper function-providing polynucleotide that encodes the viral transcription and translation factors (Ela, Elb, E2a, VA and E4) required for AAV proliferation, so as to comprise, in concert with the rAAV, a double plasmid transfection system (Grimm, D. et al. (1998)“ Novel Tools For Production And Purification Of Recombinant Adeno-Associated Virus Vectors ,” Hum. Gene Ther. 9:2745-2760; Penaud-Budloo, M. et al. (2018)“Pharmacology of Recombinant Adeno-associated Virus Production ,” Molec. Ther. Meth. Clin. Develop. 8: 166-180).

[0013] However, it has become increasingly common to clone the AAV helper function-providing polynucleotide (which provides the required rep and cap genes) into an AAV helper plasmid, and to clone the non-AAV helper function-providing polynucleotide (which provides the genes that encode the viral transcription and translation factors) on a different plasmid ( e.g. , an“Ad helper plasmid”), so that such plasmids, in concert with an rAAV plasmid vector, comprise a triple plasmid transfection system (Figure 2). Use of the triple plasmid transfection system has the advantage of permitting one to easily switch one cap gene for another, thereby facilitating changes in the rAAV’s serotype. The use of helper plasmids, rather than helper viruses, permits rAAV to be produced without additionally producing particles of the helper virus (Franqois, A. et al. (2018)“ Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls ,” Molec. Ther. Meth. Clin. Develop. 10:223-236; Matsushita, T. et al. (1998) ‘ del· lo-A ssociated Virus Vectors Can Be Efficiently Produced Without Helper Virus f Gene Ther. 5:938-945).

[0014] The transient transfection of plasmid DNAs comprising the rAAV plasmid vector, the AAV rep and cap genes, and the trans-acting AAD helper genes into HEK293 cells by calcium phosphate coprecipitation has become the standard method to produce rAAV in the research laboratory (Grimm, D. et al. (1998)“ Novel Tools For Production And Purification Of Recombinant Adeno-Associated Virus Vectors ,” Hum. Gene Ther. 9:2745-2760). However, the use of such a calcium phosphate-mediated transfection process with suspension-cultured transfected mammalian cells requires media exchanges, and is thus not considered ideal for the large-scale rAAV production that is required in order to produce therapeutic doses of rAAV (Lock, M. et al. (2010) “Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale f Hum. Gene Ther. 21 : 1259-1271). For this reason, polyethylenimine (PEI), has been used as a transfection reagent and has been found to provide yields of virus that are similar to those obtained using calcium phosphate-mediated transfection (Durocher, Y. et al. (2007)“ Scalable Serum-Free Production Of Recombinant Adeno- Associated Virus Type 2 By Transfection Of 293 Suspension Cells f J. Virol. Meth. 144:32-40).

[0015] rAAV may alternatively be produced in insect cells ( e.g. , sf9 cells) using baculoviral vectors (see, e.g. , US Patents No.: 9,879,282; 9,879,279; 8,945,918; 8,163,543; 7,271,002 and 6,723,551), or in HSV-infected baby hamster kidney (BHK) cells (e.g, BHK21) (Franqois, A. et al. (2018)“ Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls f Molec. Ther. Meth. Clin. Develop. 10:223-236). Methods of rAAV production are reviewed in Grieger, J.C. et al. (2012) “ Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications f Meth. Enzymol. 507:229- 254, and in Penaud-Budloo, M. et al. (2018)“ Pharmacology of Recombinant Adeno- associated Virus Production," Molec. Ther. Meth. Clin. Develop. 8: 166-180. IV. Methods of rAAV Purification and Recovery

[0016] After production, rAAV are typically collected and purified by one or more overnight CsCl gradient centrifugations (Zolotukhin, S. et al. (1999)“ Recombinant Adeno-Associated Virus Purification Using Novel Methods Improves Infectious Titer And Yield,” Gene Ther. 6:973-985), followed by desalting to form a purified rAAV production stock. Titers of 10 ¹² -10 ¹³ infectious rAAV capsids/mL are obtainable.

[0017] Because rAAV infection does not cause a cytopathic effect, plaque assays cannot be used to determine the infectious titer of an rAAV preparation. Infectious titer is thus typically measured as the median tissue culture infective dose (TCID50). In this method, a HeLa-derived AAV2 rep- and cap-expressing cell line is grown in a 96- well plate and infected with replicate 10-fold serial dilutions of the rAAV preparation, in the presence of adenovirus of serotype 5. After infection, vector genome replication is determined by quantitative PCR (qPCR) (Zen, Z. et al. (2004)“ Infectious Titer Assay For Adeno-Associated Virus Vectors With Sensitivity Sufficient To Detect Single Infectious Events ,” Hum. Gene Ther. 15:709-715). Alternatively, the infectious titer of an rAAV preparation can be measured using the infectious center assay (ICA). This assay uses HeLa rep-cap cells and Ad, but, after incubation, involves transferring the cells to a membrane. A labeled probe that is complementary to a portion of the employed transgene is used to detect infectious centers (representing individual infected cells) via hybridization. Although more widely used, the TCID50 assay has been reported to lead to a higher background than the ICA and to overestimate vector infectivity relative to the ICA (Franqois, A. et al. (2018)“ Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls ,” Molec. Ther. Meth. Clin. Develop. 10:223-236). Methods of producing and purifying rAAV are described inter alia in US Patents No. 10,294,452; 10,161,011; 10,017,746; 9,598,703; 7,625,570; 7,439,065; 7,419,817; 7,208,315; 6,995,006; 6,989,264; 6,846,665 and 6,841,357.

[0018] Despite all such prior advances, a need remains to develop methods capable of addressing problems that presently limit the applicability of rAAV to gene therapy (Grieger, J.C. et al. (2012)“ Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications ,” Meth. Enzymol. 507:229-254; Kotterman, M.A. et al. (2014) “Engineering Adeno-Associated Viruses For Clinical Gene Therapy ,” Nat. Rev. Genet. 15(7):445-451; Kwon, I. el al. (2007)“ Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer ,” Pharm. Res. 25(3):489-499; Naso, M.F. el al. (2017)“ Adeno-Associated Virus (AAV) as a Vector for Gene Therapy ,” BioDrugs 31 :317-334).

[0019] The present invention is directed to improved methods for increasing the efficiency of AAV and rAAV packaging through regulation of the expression of the AAV rep and cap genes.

SUMMARY OF THE INVENTION:

[0020] The present invention is directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV) and their use to improve the packaging efficiency of such rAAV. The present invention is particularly directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that have been further modified to replace (or augment) the P5 and/or P40 promoter sequences that are natively associated with the Rep proteins encoded by such rAAV with AAV P5 and/or P40 promoters that are associated with the Rep proteins of an rAAV of different serotype. The use of such substitute or additional promoter sequences causes increased production of recombinantly-modified adeno-associated virus.

[0021] In detail, the invention provides a recombinantly-modified adeno-associated virus (AAV) helper vector that comprises an AAV helper function-providing polynucleotide, and especially an AAV helper function-providing polynucleotide that is a plasmid vector, wherein the polynucleotide comprises a non-native AAV serotype P5 or P40 promoter sequence.

[0022] The invention particularly includes the embodiment of such recombinantly- modified adeno-associated virus (AAV) helper vector wherein the AAV helper function-providing polynucleotide vector comprises a non-native AAV serotype P5 promoter sequence and/or a non-native AAV serotype P40 promoter sequence. [0023] The invention also particularly includes the embodiment of such recombinantly-modified adeno-associated virus (AAV) helper vector wherein the non native AAV serotype P5 or P40 promoter sequence replaces a native AAV serotype promoter sequence.

[0024] The invention also particularly includes the embodiment of such recombinantly-modified adeno-associated virus (AAV) helper vector wherein the vector additionally comprises a non-AAV helper function-providing polynucleotide.

[0025] The invention additionally provides a method for increasing the production titer of a recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV;

(2) the above-described recombinantly-modified adeno-associated virus

(AAV) helper vector that additionally comprises a non-AAV helper functi on-provi ding poly nucl eoti de ;

wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV, and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

[0026] The invention additionally provides a method for increasing the production titer of recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV;

(2) any of the above-described recombinantly-modified adeno-associated virus (AAV) helper vectors; and

(3) an additional vector, especially a plasmid vector, that comprises a non- AAV helper function-providing polynucleotide;

wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV, and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

[0027] The invention particularly includes the embodiment of such methods, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition.

[0028] The invention also particularly includes the embodiment of such methods, wherein:

(A) the AAV helper function-providing polynucleotide of the vector encodes an AAV1 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(B) the AAV helper function-providing polynucleotide of the vector encodes an AAV2 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(C) the AAV helper function-providing polynucleotide of the vector encodes an AAV3 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(D) the AAV helper function-providing polynucleotide of the vector encodes an AAV4 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(E) the AAV helper function-providing polynucleotide of the vector encodes an AAV5 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(F) the AAV helper function-providing polynucleotide of the vector encodes an AAV6 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(G) the AAV helper function-providing polynucleotide of the vector encodes an AAV7 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV8, or a hybrid of one or more of the serotypes;

(H) the AAV helper function-providing polynucleotide of the vector encodes an AAV8 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7, or a hybrid of one or more of the serotypes.

[0029] The invention also particularly includes the embodiment of such methods, wherein the cells are human embryonic kidney cells, baby hamster kidney cells or sf9 insect cells.

[0030] The invention additionally provides a pharmaceutical composition that comprises the recombinantly-modified adeno-associated virus (rAAV) produced by any of the above-listed methods, and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS:

[0031] Figure 1 provides a schematic genetic map of the wild-type (Wt) AAV genome.

[0032] Figure 2 provides a schematic of the structural domain of the wild-type AAV2 genome (1 ), a recombinant AAV (rAAV) (2), complementing“AAV helper plasmid” (3) and an adenovirus helper plasmid (“Ad helper plasmid”) (4). The wild-type (Wt) AAV2 (1 ) is composed of AAV-specific palindromic inverted terminal repeated sequences (ITR), a 5’ half containing genes that encode the Rep proteins and a 3’ half containing genes that encode the Cap proteins. The rAAV (2) is formed by replacing the Rep- and Cap-encoding genes of the wild-type (Wt) AAV2 (1 ) with a transgene cassette that comprises a promoter (Pro), the exogenous transgene of interest, and a polyadenylation site (pA). In order to produce the rAAV (2), a complementing“AAV helper” plasmid vector (3) and an adenovirus helper plasmid vector (Ad helper plasmid) (4) are provided. The complementing AAV helper plasmid (3) provides Rep and Cap proteins. The Ad helper plasmid (4) provides adenovirus proteins Ela, Elb, E2a, VA and E4.

[0033] Figure 3 shows a map of the AAV helper plasmid vector pAAV-RCl (SEQ ID NO:l).

[0034] Figure 4 shows a map of the AAV helper plasmid vector pAAV-RC2 (SEQ ID NO:2)

[0035] Figure 5 shows a map of the AAV helper plasmid vector pAAV-RC5 (SEQ ID NO:3).

[0036] Figure 6 shows a map of the AAV helper plasmid vector pAAV-RC6 (SEQ ID NO:4).

[0037] Figure 7 shows a map of the AAV helper plasmid vector pAAV-RC7 (SEQ ID NO:5).

[0038] Figure 8 shows a map of the non-AAV helper plasmid vector pHelper-Kan (SEQ ID NO:6).

[0039] Figure 9 shows a map of the rAAV plasmid vector pAV-CMV-EGFP (SEQ ID NO:7)

[0040] Figure 10 shows a map of the rAAV plasmid vector pAV-TBG-EGFP (SEQ ID NO:8).

[0041] Figure 11 shows the overall structure and approach followed for the development of the exemplary AAV helper constructs described herein. The parent construct (pAAV-RC2; Parent-RC) comprises AAV2 serotype promoter sequences for the P5 and P19 promoters (solid black boxes) that direct expression of the native AAV2 rep gene (white boxed gene), which encodes the Rep proteins, as well as the AAV2 serotype promoter sequence of the P40 promoter (solid black box) that directs expression of the native AAV2 cap gene (gray boxed gene), which encodes the Cap proteins.

[0042] P5-RC constructs are derivatives of parental plasmid AAV RC that have been modified to direct expression of the AAV rep gene using a non-native P5 promoter (i.e., an AAV P5 promoter that is not natively present within the AAV rep gene of the vector (downward striped box)) in lieu of the native AAV serotype P5 promoter (solid black box); P5-RC constructs direct expression of the AAV rep and cap genes using the native AAV serotype P19 and P40 promoter sequences (solid black boxes) of the parent vector. P40-RC constructs are derivatives of parental plasmid AAV RC that have been modified to direct expression of the AAV cap gene using a non-native P40 promoter (i.e., an AAV P40 promoter that is not natively present within the AAV rep gene (upward striped box)) of the vector in lieu of the native AAV serotype P40 promoter (solid black box); P40-RC constructs direct expression of the AAV rep gene using the native AAV serotype P5 and P19 promoter sequences (solid black boxes) of the parent vector. P5/P40-RC constructs are derivatives of parental plasmid AAV RC that have been modified to direct expression of the AAV rep gene using a non-native P5 promoter (i.e., an AAV P5 promoter that is not natively present within the AAV rep gene of the vector (downward striped box)) in lieu of the native AAV serotype P5 promoter (solid black box). P5/P40-RC constructs have additionally been modified to direct expression to direct expression of the AAV cap gene using a non-native P40 promoter (i.e., an AAV P40 promoter that is not natively present within the AAV rep gene (upward striped box)) of the vector in lieu of the native AAV serotype P40 promoter (solid black box). P40-RC constructs direct expression of the AAV rep gene using the native AAV serotype P19 promoter sequences (solid black boxes) of the parent vector. The sequences of the promoter regions are shown in Table 1.

[0043] Figures 12A-12B show the production titers of rAAV obtained by modifying a parental RC2 vector to comprise a non-native P5 promoter sequence (Figure 11; Figure 12A; downward striped rectangle) in lieu of the AAV2 P5 promoter that is natively associated with the rep gene of such vector. The P19 and P40 promoters are both native AAV2 serotype promoter sequences (solid black rectangles). Figure 12B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. The following constructs were employed: Parent-RC2, P5(2)-RC2, P5(1)-RC2, P5(3)-RC2, P5(4)-RC2, P5(5)-RC2, P5(7)-RC2, and P5(8)-RC2 The sequences of the promoter regions are shown in Table 1. The production titers of rAAV were obtained using a triple plasmid transfection system with an rAAV, and an Ad helper plasmid that provided the required adenoviral functions.

[0044] Figures 13A-13B show the production titers of rAAV obtained by modifying a parental RC2 vector to comprise a non-native P40 promoter sequence (Figure 11; Figure 13A; upward striped rectangle) in lieu of the AAV2 serotype P40 promoter of the parental vector. The P5 and P19 promoters are both native AAV2 serotype promoter sequences (solid black rectangle). Figure 13B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. The following constructs were employed: Parent-RC2, P40(1)-RC2, P40(3)-RC2, P40(4)-RC2, P40(5)-RC2, P40(6)-RC2, P40(7)-RC2, and P40(8)-RC2. The sequences of the promoter regions are shown in Table 1. The production titers of rAAV were obtained using a triple plasmid transfection system with an rAAV, and an Ad helper plasmid that provided the required adenoviral functions.

[0045] Figures 14A-14B show the production titers of rAAV obtained by modifying a parental RC2 vector to comprise a non-native P5 promoter sequence and/or a non native P40 promoter sequence (Figure 11; Figure 14 A; P5, downward striped rectangle; P40, upward striped rectangle) in lieu of the AAV2 serotype P5 and P40 promoters of the parental vector. The P19 promoter is a native AAV2 serotype promoter sequences (solid black rectangle). The following constructs were employed: Parent-RC2, P5(2)-RC2, P5(3)-RC2, P5(5)-RC2, P40(1)-RC2, P5(2)/P40(1)-RC2, P5(3)/P40(1)-RC2, and P5(5)/P40(1)-RC2. The sequences of the promoter regions are shown in Table 1. Figure 14B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. The production titers of rAAV were obtained using a triple plasmid transfection system with an rAAV, and an Ad helper plasmid that provided the required adenoviral functions. [0046] Figures 15A-15C show the production titers of rAAV obtained by modifying a parental RC6 vector to comprise a non-native P5 promoter sequence (Figure 11; Figure 15A; downward striped rectangle) in lieu of the AAV2 serotype P5 promoter that is natively associated with the rep gene of such vector. The P19 and P40 promoters are both native AAV2 serotype promoter sequences (solid black rectangles). The following constructs were employed: Parent-RC6, P5(1)-RC6, P5(2)-RC6, P5(3)- RC6, P5(7)-RC6 and P5(8)-RC6. The sequences of the promoter regions are shown in Table 1. The production titers of rAAV were obtained (Figures 15B-15C) using a triple plasmid transfection system with an rAAV, and an Ad helper plasmid that provided the required adenoviral functions.

[0047] Figures 16A-16B show the production titers of rAAV obtained by modifying a parental RC1, RC5, or RC7 vector to comprise a non-native P5 promoter sequence (Figure 11; Figure 16A; downward striped rectangle) in lieu of the AAV2 serotype P5 promoter that is natively associated with the rep gene of such vectors. The P19 and P40 promoters are both native AAV2 serotype promoter sequences (solid black rectangles). The following constructs were employed: Parent-RCl, Parent-RC5, Parent-RC7, P5(2)-RC1, P5(7)-RC1, P5(8)-RC1, P5(7)-RC5, P5(2)-RC7, P5(7)- RC7 and P5(8)-RC7. The sequences of the promoter regions are shown in Table 1. The production titers of rAAV (Figure 16B) were obtained using a triple plasmid transfection system with an rAAV, and an Ad helper plasmid that provided the required adenoviral functions.

DETAILED DESCRIPTION OF THE INVENTION:

I. The Methods of the Present Invention

[0048] The present invention is directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV) and their use to improve the packaging efficiency of such rAAV. The present invention is particularly directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that have been further modified to replace (or augment) the P5 and/or P40 promoter sequences that are natively associated with the Rep proteins encoded by such rAAV with AAV P5 and/or P40 promoters that are associated with the Rep proteins of an rAAV of different serotype. The use of such substitute or additional promoter sequences causes increased production of recombinantly-modified adeno-associated virus.

[0049] The present invention is based in part on the recognition that high levels of Rep and Cap proteins increase the amount of rAAV genomes particles produced and, consequently, the efficiency of rAAV packaging, and thus result in high production titers of rAAV stocks. It has been unexpectedly found that by replacing the AAV P5 and/or P40 promoters that direct the expression of the Cap proteins with different AAV P5 and/or P40 promoters, or by adding such different AAV P5 and/or P40 promoters in addition to those initially present, causes the desired high levels of rAAV to be attained. AAV Rep proteins are described in US Patents No. 10,214,730; 7,122,348; 6,821,511; 6,753,419; 9,441,206; and 7,115,391.

[0050] As discussed above, AAV and rAAV are characterized based on their serotype, which is determined by their capsid proteins (Colella, P. et al. (2018) “Emerging Issues in AAV-Mediated In Vivo Gene Therapy ,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Hocquemiller, M. et al. (2016)“ Adeno-Associated Virus-Based Gene Therapy for CNS Diseases ,” Hum. Gene Ther. 27(7):478-496; Lisowski, L. et al. (2015)“ Adeno-Associated Virus Serotypes For Gene Therapeutics ,” 24:59-67; US Patents No. 10,301,650; 10,266,846; 10,265,417; 10,214,785; 10,214,566; 10,202,657; 10,046,016; 9,884,071; 9,856,539; 9,737,618; 9,677,089; 9,458,517; 9,457,103; 9,441,244; 9,193,956; 8,846,389; 8,507,267; 7,906, 111; 7,479,554; 7, 186,552; 7, 105,345; 6,984,517; 6,962,815; and 6,733,757). By forming AAV and rAAV in the presence of AAV helper function-providing polynucleotides that encode two or more capsid proteins of different serotype, one can produce AAV and rAAV having“hybrid” serotypes. Such AAV and rAAV exhibit the combined trophism of AAV and rAAV having each of such capsid proteins.

[0051] The Rep proteins of the different AAV serotypes differ, however, since such proteins are not structural proteins, the differences do not contribute to the observed serotype of an AAV.

[0052] As used herein, the term“AAV” is intended to denote adeno-associated virus, and may be used to refer to the virus itself or derivatives thereof. The term covers all subtypes and both naturally-occurring and recombinant forms. As used herein, the term “rAAV” is intended to denote a recombinantly-modified version of AAV that comprises a polynucleotide sequence not of AAV origin ( i.e ., a polynucleotide heterologous to AAV). The rAAV may be single-stranded or double-stranded, and may be composed of deoxyribonucleotides or ribonucleotides. As discussed above, rAAV typically lack certain AAV genes and thus are produced using a double plasmid transfection system, or more preferably a triple plasmid transfection system that comprises a plasmid vector that comprises an AAV helper function-providing polynucleotide, a plasmid vector that comprises a non-AAV helper functionproviding polynucleotide, and the rAAV plasmid vector (Figure 2). In one embodiment, the AAV helper function-providing polynucleotide of such double or triple transfection systems may comprise more than one rep and/or cap gene, so as to be capable of forming rAAV having hybrid serotypes. In another embodiment, a second or additional AAV helper function-providing polynucleotide (for example on a second or additional plasmid vector) may be provided to permit the formation of rAAV having hybrid serotypes.

A. Illustrative AAV Helper Function-Providing Polynucleotides

[0053] As used herein, the term“AAV helper functions” denotes AAV proteins ( e.g . , Rep and Cap) and/or polynucleotides of AAV that are required for the replication and packaging of an rAAV. Such AAV helper functions are provided by an“AAV helper function-providing polynucleotide,” which as such term is used herein is a virus, plasmid vector, a non-plasmid vector, or a polynucleotide that has been integrated into a cellular chromosome, that provides AAV helper functions. AAV helper plasmids that may be used in accordance with the present invention to provide AAV helper functions include pAAV-RC (Agilent; Addgene; Cell Biolabs), pAAV-RCl, pAAV-RC2, pAAV-RC5, pAAV-RC6, and pAAV-RC7

1. Plasmid pAAV-RCl

[0054] Plasmid pAAV-RCl (SEQ ID NO:l; Figure 3) is an AAV helper plasmid that expresses AAV1 serotype capsid proteins that may be used in accordance with the present invention to provide AAV helper functions. The P5 and P40 promoters of pAAV-RCl are AAV2 serotype promoters (SEQ ID NO: 10 and SEQ ID NO: 18, respectively). Coding Strand of Plasmid pAAV-RCl (SEQ ID NO:l):

catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc tctctgaggg cattcgcgag tggtgggact tgaaacctgg agccccgaag cccaaagcca accagcaaaa gcaggacgac ggccggggtc tggtgcttcc tggctacaag tacctcggac ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggacgcagcg gccctcgagc acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcttttggg ggcaacctcg ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg gttgaggaag gcgctaagac ggctcctgga aagaaacgtc cggtagagca gtcgccacaa gagccagact cctcctcggg catcggcaag acaggccagc agcccgctaa aaagagactc aattttggtc agactggcga ctcagagtca gtccccgatc cacaacctct cggagaacct ccagcaaccc ccgctgctgt gggacctact acaatggctt caggcggtgg cgcaccaatg gcagacaata acgaaggcgc cgacggagtg ggtaatgcct caggaaattg gcattgcgat tccacatggc tgggcgacag agtcatcacc accagcaccc gcacctgggc cttgcccacc tacaataacc acctctacaa gcaaatctcc agtgcttcaa cgggggccag caacgacaac cactacttcg gctacagcac cccctggggg tattttgatt tcaacagatt ccactgccac ttttcaccac gtgactggca gcgactcatc aacaacaatt ggggattccg gcccaagaga ctcaacttca aactcttcaa catccaagtc aaggaggtca cgacgaatga tggcgtcaca accatcgcta ataaccttac cagcacggtt caagtcttct cggactcgga gtaccagctt ccgtacgtcc tcggctctgc gcaccagggc tgcctccctc cgttcccggc ggacgtgttc atgattccgc aatacggcta cctgacgctc aacaatggca gccaagccgt gggacgttca tccttttact gcctggaata tttcccttct cagatgctga gaacgggcaa caactttacc ttcagctaca cctttgagga agtgcctttc cacagcagct acgcgcacag ccagagcctg gaccggctga tgaatcctct catcgaccaa tacctgtatt acctgaacag aactcaaaat cagtccggaa gtgcccaaaa caaggacttg ctgtttagcc gtgggtctcc agctggcatg tctgttcagc ccaaaaactg gctacctgga ccctgttatc ggcagcagcg cgtttctaaa acaaaaacag acaacaacaa cagcaatttt acctggactg gtgcttcaaa atataacctc aatgggcgtg aatccatcat caaccctggc actgctatgg cctcacacaa agacgacgaa gacaagttct ttcccatgag cggtgtcatg atttttggaa aagagagcgc cggagcttca aacactgcat tggacaatgt catgattaca gacgaagagg aaattaaagc cactaaccct gtggccaccg aaagatttgg gaccgtggca gtcaatttcc agagcagcag cacagaccct gcgaccggag atgtgcatgc tatgggagca ttacctggca tggtgtggca agatagagac gtgtacctgc agggtcccat ttgggccaaa attcctcaca cagatggaca ctttcacccg tctcctctta tgggcggctt tggactcaag aacccgcctc ctcagatcct catcaaaaac acgcctgttc ctgcgaatcc tccggcggag ttttcagcta caaagtttgc ttcattcatc acccaatact ccacaggaca agtgagtgtg gaaattgaat gggagctgca gaaagaaaac agcaagcgct ggaatcccga agtgcagtac acatccaatt atgcaaaatc tgccaacgtt gattttactg tggacaacaa tggactttat actgagcctc gccccattgg cacccgttac cttacccgtc ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa ccgtttaatt cgtttcagtt gaactttggt ctctgcgtat ttctttctta tctagtttcc atgctctagg atccactagt aacggccgcc agtgtgctgg aattcggctt tgtagttaat gattaacccg ccatgctact tatctacgta gccatgctct agaggtcctg tattagaggt cacgtgagtg ttttgcgaca ttttgcgaca ccatgtggtc acgctgggta tttaagcccg agtgagcacg cagggtctcc attttgaagc gggaggtttg aacgcgcagc cgccaagccg aattctgcag atatccaaac actggcggcc gctcgactag agcggccgcc accgcggtgg agctccagct tttgttccct ttagtgaggg ttaattgcgc gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctaa attgtaagcg ttaatatttt gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt tggggtcgag gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag cttgacgggg aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc gctacagggc gcgtcccatt cgccattcag gctgcgcaac tgttgggaag ggcgatcggt gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa acgacggcca gtgagcgcgc gtaatacgac tcactatagg gcgaattggg taccgggccc cccctcgagg tcgacggtat cgggggagct cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca gccgccatgc cggggtttta cgagattgtg attaaggtcc ccagcgacct tgacgagcat ctgcccggca tttctgacag ctttgtgaac tgggtggccg agaaggaatg ggagttgccg ccagattctg acatggatct gaatctgatt gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg actttctgac ggaatggcgc cgtgtgagta aggccccgga ggctcttttc tttgtgcaat ttgagaaggg agagagctac ttccacatgc acgtgctcgt ggaaaccacc ggggtgaaat c [0055] In SEQ ID NO:l, residues 1-1561 of pAAV-RCl encode the Rep protein, Rep78 (with residues 95-221 corresponding to the AAV2 P19 promoter and residues 1075-1254 corresponding to the AAV2 P40 promoter (SEQ ID NO:18)); residues 1578-3788 encode the AAV1 VP1 capsid protein; residues 7127-7431 encode a portion of the Rep68 protein; residues 3984-4114 correspond to AAV2 P5 promoter sequences (SEQ ID NO:10); residues 4237-4253 are M13 Rev sequences; residues 4261-4277 are Lac operator sequences; 4285-4315 are Lac promoter sequences; residues 4578-5302 correspond to pMB ori sequences, residues 5398-6258 encode an ampicillin resistance determinant; and residues 6259-6357 are bla promoter sequences (Figure 3).

2. Plasmid pAAV-RC2

[0056] Plasmid pAAV-RC2 (SEQ ID NO:2; Figure 4) is an AAV helper plasmid that expresses AAV2 serotype capsid proteins that may be used in accordance with the present invention to provide AAV helper functions. The P5 and P40 promoters of pAAV-RC2 are AAV2 serotype promoters (SEQ ID NO: 10 and SEQ ID NO: 18, respectively).

Coding Strand of Plasmid pAAV-RC2 (SEQ ID NO:2):

ccgggccccc cctcgaggtc gacggtatcg ggggagctcg cagggtctcc attttgaagc gggaggtttg aacgcgcagc cgccatgccg gggttttacg agattgtgat taaggtcccc agcgaccttg acgagcatct gcccggcatt tctgacagct ttgtgaactg ggtggccgag aaggaatggg agttgccgcc agattctgac atggatctga atctgattga gcaggcaccc ctgaccgtgg ccgagaagct gcagcgcgac tttctgacgg aatggcgccg tgtgagtaag gccccggagg ctcttttctt tgtgcaattt gagaagggag agagctactt ccacatgcac gtgctcgtgg aaaccaccgg ggtgaaatcc atggttttgg gacgtttcct gagtcagatt cgcgaaaaac tgattcagag aatttaccgc gggatcgagc cgactttgcc aaactggttc gcggtcacaa agaccagaaa tggcgccgga ggcgggaaca aggtggtgga tgagtgctac atccccaatt acttgctccc caaaacccag cctgagctcc agtgggcgtg gactaatatg gaacagtatt taagcgcctg tttgaatctc acggagcgta aacggttggt ggcgcagcat ctgacgcacg tgtcgcagac gcaggagcag aacaaagaga atcagaatcc caattctgat gcgccggtga tcagatcaaa aacttcagcc aggtacatgg agctggtcgg gtggctcgtg gacaagggga ttacctcgga gaagcagtgg atccaggagg accaggcctc atacatctcc ttcaatgcgg cctccaactc gcggtcccaa atcaaggctg ccttggacaa tgcgggaaag attatgagcc tgactaaaac cgcccccgac tacctggtgg gccagcagcc cgtggaggac atttccagca atcggattta taaaattttg gaactaaacg ggtacgatcc ccaatatgcg gcttccgtct ttctgggatg ggccacgaaa aagttcggca agaggaacac catctggctg tttgggcctg caactaccgg gaagaccaac atcgcggagg ccatagccca cactgtgccc ttctacgggt gcgtaaactg gaccaatgag aactttccct tcaacgactg tgtcgacaag atggtgatct ggtgggagga ggggaagatg accgccaagg tcgtggagtc ggccaaagcc attctcggag gaagcaaggt gcgcgtggac cagaaatgca agtcctcggc ccagatagac ccgactcccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga cgggaactca acgaccttcg aacaccagca gccgttgcaa gaccggatgt tcaaatttga actcacccgc cgtctggatc atgactttgg gaaggtcacc aagcaggaag tcaaagactt tttccggtgg gcaaaggatc acgtggttga ggtggagcat gaattctacg tcaaaaaggg tggagccaag aaaagacccg cccccagtga cgcagatata agtgagccca aacgggtgcg cgagtcagtt gcgcagccat cgacgtcaga cgcggaagct tcgatcaact acgcagacag gtaccaaaac aaatgttctc gtcacgtggg catgaatctg atgctgtttc cctgcagaca atgcgagaga atgaatcaga attcaaatat ctgcttcact cacggacaga aagactgttt agagtgcttt cccgtgtcag aatctcaacc cgtttctgtc gtcaaaaagg cgtatcagaa actgtgctac attcatcata tcatgggaaa ggtgccagac gcttgcactg cctgcgatct ggtcaatgtg gatttggatg actgcatctt tgaacaataa atgatttaaa tcaggtatgg ctgccgatgg ttatcttcca gattggctcg aggacactct ctctgaagga ataagacagt ggtggaagct caaacctggc ccaccaccac caaagcccgc agagcggcat aaggacgaca gcaggggtct tgtgcttcct gggtacaagt acctcggacc cttcaacgga ctcgacaagg gagagccggt caacgaggca gacgccgcgg ccctcgagca cgacaaagcc tacgaccggc agctcgacag cggagacaac ccgtacctca agtacaacca cgccgacgcg gagtttcagg agcgccttaa agaagatacg tcttttgggg gcaacctcgg acgagcagtc ttccaggcga aaaagagggt tcttgaacct ctgggcctgg ttgaggaacc tgttaagacg gctccgggaa aaaagaggcc ggtagagcac tctcctgtgg agccagactc ctcctcggga accggaaagg cgggccagca gcctgcaaga aaaagattga attttggtca gactggagac gcagactcag tacctgaccc ccagcctctc ggacagccac cagcagcccc ctctggtctg ggaactaata cgatggctac aggcagtggc gcaccaatgg cagacaataa cgagggcgcc gacggagtgg gtaattcctc gggaaattgg cattgcgatt ccacatggat gggcgacaga gtcatcacca ccagcacccg aacctgggcc ctgcccacct acaacaacca cctctacaaa caaatttcca gccaatcagg agcctcgaac gacaatcact actttggcta cagcacccct tgggggtatt ttgacttcaa cagattccac tgccactttt caccacgtga ctggcaaaga ctcatcaaca acaactgggg attccgaccc aagagactca acttcaagct ctttaacatt caagtcaaag aggtcacgca gaatgacggt acgacgacga ttgccaataa ccttaccagc acggttcagg tgtttactga ctcggagtac cagctcccgt acgtcctcgg ctcggcgcat caaggatgcc tcccgccgtt cccagcagac gtcttcatgg tgccacagta tggatacctc accctgaaca acgggagtca ggcagtagga cgctcttcat tttactgcct ggagtacttt ccttctcaga tgctgcgtac cggaaacaac tttaccttca gctacacttt tgaggacgtt cctttccaca gcagctacgc tcacagccag agtctggacc gtctcatgaa tcctctcatc gaccagtacc tgtattactt gagcagaaca aacactccaa gtggaaccac cacgcagtca aggcttcagt tttctcaggc cggagcgagt gacattcggg accagtctag gaactggctt cctggaccct gttaccgcca gcagcgagta tcaaagacat ctgcggataa caacaacagt gaatactcgt ggactggagc taccaagtac cacctcaatg gcagagactc tctggtgaat ccgggcccgg ccatggcaag ccacaaggac gatgaagaaa agttttttcc tcagagcggg gttctcatct ttgggaagca aggctcagag aaaacaaatg tggacattga aaaggtcatg attacagacg aagaggaaat caggacaacc aatcccgtgg ctacggagca gtatggttct gtatctacca acctccagag aggcaacaga caagcagcta ccgcagatgt caacacacaa ggcgttcttc caggcatggt ctggcaggac agagatgtgt accttcaggg gcccatctgg gcaaagattc cacacacgga cggacatttt cacccctctc ccctcatggg tggattcgga cttaaacacc ctcctccaca gattctcatc aagaacaccc cggtacctgc gaatccttcg accaccttca gtgcggcaaa gtttgcttcc ttcatcacac agtactccac gggacaggtc agcgtggaga tcgagtggga gctgcagaag gaaaacagca aacgctggaa tcccgaaatt cagtacactt ccaactacaa caagtctgtt aatgtggact ttactgtgga cactaatggc gtgtattcag agcctcgccc cattggcacc agatacctga ctcgtaatct gtaattgctt gttaatcaat aaaccgttta attcgtttca gttgaacttt ggtctctgcg tatttctttc ttatctagtt tccatgctct aggatccact agtaacggcc gccagtgtgc tggaattcgg ctttgtagtt aatgattaac ccgccatgct acttatctac gtagccatgc tctagaggtc ctgtattaga ggtcacgtga gtgttttgcg acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc acgcagggtc tccattttga agcgggaggt ttgaacgcgc agccgccaag ccgaattctg cagatatcca aacactggcg gccgctcgac tagagcggcc gccaccgcgg tggagctcca gcttttgttc cctttagtga gggttaattg cgcgcttggc gtaatcatgg tcatagctgt ttcctgtgtg aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga agaacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa aagtgccacc taaattgtaa gcgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatgc gccgctacag ggcgcgtccc attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt tttcccagtc acgacgttgt aaaacgacgg ccagtgagcg cgcgtaatac gactcactat agggcgaatt gggta

[0057] In SEQ ID NO:2, residues 85-1950 of pAAV-RC2 encode the Rep protein, Rep78 (with residues 484-663 corresponding to the AAV2 P19 promoter, residues 1464-1643 corresponding to the AAV2 P40 promoter (SEQ ID NO:18) and residues 1668-1676 being a donor site); residues 1967-4174 encode the AAV2 VP1 capsid protein; residues 1992-2016 encode a portion of the Rep68 protein; residues 4175-4256 encode a polyA sequence; residues 4357-4487 correspond to the AAV2 P5 promoter sequences of SEQ ID NO:10); residues 4610-4626 are M13 Rev sequences; residues 4634-4650 are Lac operator sequences; 4658-4688 are Lac promoter sequences; residues 4951-5675 correspond to pMB on sequences, residues 5771-6631 encode an ampicillin resistance determinant; and residues 6632-6730 are bla promoter sequences (Figure 4).

3. Plasmid pAAV-RC5

[0058] Plasmid pAAV-RC5 (SEQ ID NO:3; Figure 5) is an AAV helper plasmid that expresses AAV5 serotype capsid proteins that may be used in accordance with the present invention to provide AAV helper functions. The P5 and P40 promoters of pAAV-RC5 are AAV2 serotype promoters (SEQ ID NO: 10 and SEQ ID NO: 18, respectively).

Coding Strand of Plasmid pAAV-RC5 (SEQ ID NO:3):

catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata aatgatttaa atcaggtatg tcttttgttg atcaccctcc agattggttg gaagaagttg gtgaaggtct tcgcgagttt ttgggccttg aagcgggccc accgaaacca aaacccaatc agcagcatca agatcaagcc cgtggtcttg tgctgcctgg ttataactat ctcggacccg gaaacggtct cgatcgagga gagcctgtca acagggcaga cgaggtcgcg cgagagcacg acatctcgta caacgagcag cttgaggcgg gagacaaccc ctacctcaag tacaaccacg cggacgccga gtttcaggag aagctcgccg acgacacatc cttcggggga aacctcggaa aggcagtctt tcaggccaag aaaagggttc tcgaaccttt tggcctggtt gaagagggtg ctaagacggc ccctaccgga aagcggatag acgaccactt tccaaaaaga aagaaggctc ggaccgaaga ggactccaag ccttccacct cgtcagacgc cgaagctgga cccagcggat cccagcagct gcaaatccca gcccaaccag cctcaagttt gggagctgat acaatgtctg cgggaggtgg cggcccattg ggcgacaata accaaggtgc cgatggagtg ggcaatgcct cgggagattg gcattgcgat tccacgtgga tgggggacag agtcgtcacc aagtccaccc gaacctgggt gctgcccagc tacaacaacc accagtaccg agagatcaaa agcggctccg tcgacggaag caacgccaac gcctactttg gatacagcac cccctggggg tactttgact ttaaccgctt ccacagccac tggagccccc gagactggca aagactcatc aacaactact ggggcttcag accccggtcc ctcagagtca aaatcttcaa cattcaagtc aaagaggtca cggtgcagga ctccaccacc accatcgcca acaacctcac ctccaccgtc caagtgttta cggacgacga ctaccagctg ccctacgtcg tcggcaacgg gaccgaggga tgcctgccgg ccttccctcc gcaggtcttt acgctgccgc agtacggtta cgcgacgctg aaccgcgaca acacagaaaa tcccaccgag aggagcagct tcttctgcct agagtacttt cccagcaaga tgctgagaac gggcaacaac tttgagttta cctacaactt tgaggaggtg cccttccact ccagcttcgc tcccagtcag aacctgttca agctggccaa cccgctggtg gaccagtact tgtaccgctt cgtgagcaca aataacactg gcggagtcca gttcaacaag aacctggccg ggagatacgc caacacctac aaaaactggt tcccggggcc catgggccga acccagggct ggaacctggg ctccggggtc aaccgcgcca gtgtcagcgc cttcgccacg accaatagga tggagctcga gggcgcgagt taccaggtgc ccccgcagcc gaacggcatg accaacaacc tccagggcag caacacctat gccctggaga acactatgat cttcaacagc cagccggcga acccgggcac caccgccacg tacctcgagg gcaacatgct catcaccagc gagagcgaga cgcagccggt gaaccgcgtg gcgtacaacg tcggcgggca gatggccacc aacaaccaga gctccaccac tgcccccgcg accggcacgt acaacctcca ggaaatcgtg cccggcagcg tgtggatgga gagggacgtg tacctccaag gacccatctg ggccaagatc ccagagacgg gggcgcactt tcacccctct ccggccatgg gcggattcgg actcaaacac ccaccgccca tgatgctcat caagaacacg cctgtgcccg gaaatatcac cagcttctcg gacgtgcccg tcagcagctt catcacccag tacagcaccg ggcaggtcac cgtggagatg gagtgggagc tcaagaagga aaactccaag aggtggaacc cagagatcca gtacacaaac aactacaacg acccccagtt tgtggacttt gccccggaca gcaccgggga atacagaacc accagaccta tcggaacccg ataccttacc cgaccccttt aaggcgcgcc accggttgct tgttaatcaa taaaccgttt aattcgtttc agttgaactt tggtctctgc gtatttcttt cttatctagt ttccatgctc taggatccac tagtaacggc cgccagtgtg ctggaattcg gctttgtagt taatgattaa cccgccatgc tacttatcta cgtagccatg ctctagaggt cctgtattag aggtcacgtg agtgttttgc gacattttgc gacaccatgt ggtcacgctg ggtatttaag cccgagtgag cacgcagggt ctccattttg aagcgggagg tttgaacgcg cagccgccaa gccgaattct gcagatatcc aaacactggc ggccgctcga ctagagcggc cgccaccgcg gtggagctcc agcttttgtt ccctttagtg agggttaatt gcgcgcttgg cgtaatcatg gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctaaattgta agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt tttttggggt cgaggtgccg taaagcacta aatcggaacc ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc gcgcttaatg cgccgctaca gggcgcgtcc cattcgccat tcaggctgcg caactgttgg gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt cacgacgttg taaaacgacg gccagtgagc gcgcgtaata cgactcacta tagggcgaat tgggtaccgg gccccccctc gaggtcgacg gtatcggggg agctcgcagg gtctccattt tgaagcggga ggtttgaacg cgcagccgcc atgccggggt tttacgagat tgtgattaag gtccccagcg accttgacga gcatctgccc ggcatttctg acagctttgt gaactgggtg gccgagaagg aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcag gcacccctga ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc cggaggctct tttctttgtg caatttgaga agggagagag ctacttccac atgcacgtgc tcgtggaaac caccggggtg aaatc

[0059] In SEQ ID NO:3, residues 1-1561 of pAAV-RC5 encode the Rep protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19 promoter, and residues 1075-1254 corresponding to the P40 promoter (SEQ ID NO:18)); residues 1578-3749 encode the AAV5 VP1 capsid protein; residues 7091-7395 encode a portion of the Rep68 protein; residues 3948-4078 correspond to the AAV2 P5 promoter sequences of SEQ ID NO: 10); residues 4201-4217 are Ml 3 Rev sequences; residues 4225-4241 are Lac operator sequences; 4249-4279 are Lac promoter sequences; residues 4542-5266 correspond to pMB ori sequences, residues 5362-6222 encode an ampicillin resistance determinant; and residues 6223-6321 are bla promoter sequences (Figure 5).

4. Plasmid pAAV-RC6

[0060] Plasmid pAAV-RC6 (SEQ ID NO:4; Figure 6) is an AAV helper plasmid that expresses AAV6 serotype capsid proteins that may be used in accordance with the present invention to provide AAV helper functions. The P5 and P40 promoters of pAAV-RC6 are AAV2 serotype promoters (SEQ ID NO: 10 and SEQ ID NO: 18, respectively).

Coding Strand of Plasmid pAAV-RC6 (SEQ ID NO:4):

catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc tctctgaggg cattcgcgag tggtgggact tgaaacctgg agccccgaaa cccaaagcca accagcaaaa gcaggacgac ggccggggtc tggtgcttcc tggctacaag tacctcggac ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggatgcagcg gccctcgagc acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcttttggg ggcaacctcg ggcgagcagt cttccaggcc aagaagaggg ttctcgaacc ttttggtctg gttgaggaag gtgctaagac ggctcctgga aagaaacgtc cggtagagca gtcgccacaa gagccagact cctcctcggg cattggcaag acaggccagc agcccgctaa aaagagactc aattttggtc agactggcga ctcagagtca gtccccgacc cacaacctct cggagaacct ccagcaaccc ccgctgctgt gggacctact acaatggctt caggcggtgg cgcaccaatg gcagacaata acgaaggcgc cgacggagtg ggtaatgcct caggaaattg gcattgcgat tccacatggc tgggcgacag agtcatcacc accagcaccc gaacatgggc cttgcccacc tataacaacc acctctacaa gcaaatctcc agtgcttcaa cgggggccag caacgacaac cactacttcg gctacagcac cccctggggg tattttgatt tcaacagatt ccactgccat ttctcaccac gtgactggca gcgactcatc aacaacaatt ggggattccg gcccaagaga ctcaacttca agctcttcaa catccaagtc aaggaggtca cgacgaatga tggcgtcacg accatcgcta ataaccttac cagcacggtt caagtcttct cggactcgga gtaccagttg ccgtacgtcc tcggctctgc gcaccagggc tgcctccctc cgttcccggc ggacgtgttc atgattccgc agtacggcta cctaacgctc aacaatggca gccaggcagt gggacggtca tccttttact gcctggaata tttcccatcg cagatgctga gaacgggcaa taactttacc ttcagctaca ccttcgagga cgtgcctttc cacagcagct acgcgcacag ccagagcctg gaccggctga tgaatcctct catcgaccag tacctgtatt acctgaacag aactcagaat cagtccggaa gtgcccaaaa caaggacttg ctgtttagcc gggggtctcc agctggcatg tctgttcagc ccaaaaactg gctacctgga ccctgttacc ggcagcagcg cgtttctaaa acaaaaacag acaacaacaa cagcaacttt acctggactg gtgcttcaaa atataacctt aatgggcgtg aatctataat caaccctggc actgctatgg cctcacacaa agacgacaaa gacaagttct ttcccatgag cggtgtcatg atttttggaa aggagagcgc cggagcttca aacactgcat tggacaatgt catgatcaca gacgaagagg aaatcaaagc cactaacccc gtggccaccg aaagatttgg gactgtggca gtcaatctcc agagcagcag cacagaccct gcgaccggag atgtgcatgt tatgggagcc ttacctggaa tggtgtggca agacagagac gtatacctgc agggtcctat ttgggccaaa attcctcaca cggatggaca ctttcacccg tctcctctca tgggcggctt tggacttaag cacccgcctc ctcagatcct catcaaaaac acgcctgttc ctgcgaatcc tccggcagag ttttcggcta caaagtttgc ttcattcatc acccagtatt ccacaggaca agtgagcgtg gagattgaat gggagctgca gaaagaaaac agcaaacgct ggaatcccga agtgcagtat acatctaact atgcaaaatc tgccaacgtt gatttcactg tggacaacaa tggactttat actgagcctc gccccattgg cacccgttac ctcacccgtc ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa ccgtttaatt cgtttcagtt gaactttggt ctctgcgtat ttctttctta tctagtttcc atgctctagg atccactagt aacggccgcc agtgtgctgg aattcggctt tgtagttaat gattaacccg ccatgctact tatctacgta gccatgctct agaggtcctg tattagaggt cacgtgagtg ttttgcgaca ttttgcgaca ccatgtggtc acgctgggta tttaagcccg agtgagcacg cagggtctcc attttgaagc gggaggtttg aacgcgcagc cgccaagccg aattctgcag atatccaaac actggcggcc gctcgactag agcggccgcc accgcggtgg agctccagct tttgttccct ttagtgaggg ttaattgcgc gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctaa attgtaagcg ttaatatttt gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt tggggtcgag gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag cttgacgggg aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc gctacagggc gcgtcccatt cgccattcag gctgcgcaac tgttgggaag ggcgatcggt gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa acgacggcca gtgagcgcgc gtaatacgac tcactatagg gcgaattggg taccgggccc cccctcgagg tcgacggtat cgggggagct cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca gccgccatgc cggggtttta cgagattgtg attaaggtcc ccagcgacct tgacgagcat ctgcccggca tttctgacag ctttgtgaac tgggtggccg agaaggaatg ggagttgccg ccagattctg acatggatct gaatctgatt gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg actttctgac ggaatggcgc cgtgtgagta aggccccgga ggctcttttc tttgtgcaat ttgagaaggg agagagctac ttccacatgc acgtgctcgt ggaaaccacc ggggtgaaat c

[0061] In SEQ ID NO:4, residues 1-1561 of pAAV-RC6 encode the Rep protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19 promoter, and residues 1075-1254 corresponding to the P40 promoter (SEQ ID NO:18)); residues 1578-3788 encode the AAV6 VP1 capsid protein; residues 736-1281 encode a portion of the Rep68 protein; residues 3984-4114 correspond to the AAV2 P5 promoter sequences of SEQ ID NO:10); residues 4237-4253 are Ml 3 Rev sequences; residues 4261-4277 are Lac operator sequences; 4285-4315 are Lac promoter sequences; residues 4578-5302 correspond to pMB ori sequences, residues 5398-6258 encode an ampicillin resistance determinant; and residues 6259-6357 are bla promoter sequences (Figure 6).

5. Plasmid pAAV-RC7

[0062] Plasmid pAAV-RC7 (SEQ ID NO:5; Figure 7) is an AAV helper plasmid that expresses AAV6 serotype capsid proteins that may be used in accordance with the present invention to provide AAV helper functions. The P5 and P40 promoters of pAAV-RC7 are AAV2 serotype promoters (SEQ ID NO: 10 and SEQ ID NO: 18, respectively).

Coding Strand of Plasmid pAAV-RC7 (SEQ ID NO:5):

catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc tctctgaggg cattcgcgag tggtgggacc tgaaacctgg agccccgaaa cccaaagcca accagcaaaa gcaggacaac ggccggggtc tggtgcttcc tggctacaag tacctcggac ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggacgcagcg gccctcgagc acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcatttggg ggcaacctcg ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg gttgaggaag gcgctaagac ggctcctgca aagaagagac cggtagagcc gtcacctcag cgttcccccg actcctccac gggcatcggc aagaaaggcc agcagcccgc cagaaagaga ctcaatttcg gtcagactgg cgactcagag tcagtccccg accctcaacc tctcggagaa cctccagcag cgccctctag tgtgggatct ggtacagtgg ctgcaggcgg tggcgcacca atggcagaca ataacgaagg tgccgacgga gtgggtaatg cctcaggaaa ttggcattgc gattccacat ggctgggcga cagagtcatt accaccagca cccgaacctg ggccctgccc acctacaaca accacctcta caagcaaatc tccagtgaaa ctgcaggtag taccaacgac aacacctact tcggctacag caccccctgg gggtattttg actttaacag attccactgc cacttctcac cacgtgactg gcagcgactc atcaacaaca actggggatt ccggcccaag aagctgcggt tcaagctctt caacatccag gtcaaggagg tcacgacgaa tgacggcgtt acgaccatcg ctaataacct taccagcacg attcaggtat tctcggactc ggaataccag ctgccgtacg tcctcggctc tgcgcaccag ggctgcctgc ctccgttccc ggcggacgtc ttcatgattc ctcagtacgg ctacctgact ctcaacaatg gcagtcagtc tgtgggacgt tcctccttct actgcctgga gtacttcccc tctcagatgc tgagaacggg caacaacttt gagttcagct acagcttcga ggacgtgcct ttccacagca gctacgcaca cagccagagc ctggaccggc tgatgaatcc cctcatcgac cagtacttgt actacctggc cagaacacag agtaacccag gaggcacagc tggcaatcgg gaactgcagt tttaccaggg cgggccttca actatggccg aacaagccaa gaattggtta cctggacctt gcttccggca acaaagagtc tccaaaacgc tggatcaaaa caacaacagc aactttgctt ggactggtgc caccaaatat cacctgaacg gcagaaactc gttggttaat cccggcgtcg ccatggcaac tcacaaggac gacgaggacc gctttttccc atccagcgga gtcctgattt ttggaaaaac tggagcaact aacaaaacta cattggaaaa tgtgttaatg acaaatgaag aagaaattcg tcctactaat cctgtagcca cggaagaata cgggatagtc agcagcaact tacaagcggc taatactgca gcccagacac aagttgtcaa caaccaggga gccttacctg gcatggtctg gcagaaccgg gacgtgtacc tgcagggtcc catctgggcc aagattcctc acacggatgg caactttcac ccgtctcctt tgatgggcgg ctttggactt aaacatccgc ctcctcagat cctgatcaag aacactcccg ttcccgctaa tcctccggag gtgtttactc ctgccaagtt tgcttcgttc atcacacagt acagcaccgg acaagtcagc gtggaaatcg agtgggagct gcagaaggaa aacagcaagc gctggaaccc ggagattcag tacacctcca actttgaaaa gcagactggt gtggactttg ccgttgacag ccagggtgtt tactctgagc ctcgccctat tggcactcgt tacctcaccc gtaatctgta aggcgcgcca ccggttgctt gttaatcaat aaaccgttta attcgtttca gttgaacttt ggtctctgcg tatttctttc ttatctagtt tccatgctct aggatccact agtaacggcc gccagtgtgc tggaattcgg ctttgtagtt aatgattaac ccgccatgct acttatctac gtagccatgc tctagaggtc ctgtattaga ggtcacgtga gtgttttgcg acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc acgcagggtc tccattttga agcgggaggt ttgaacgcgc agccgccaag ccgaattctg cagatatcca aacactggcg gccgctcgac tagagcggcc gccaccgcgg tggagctcca gcttttgttc cctttagtga gggttaattg cgcgcttggc gtaatcatgg tcatagctgt ttcctgtgtg aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga agaacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa aagtgccacc taaattgtaa gcgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatgc gccgctacag ggcgcgtccc attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt tttcccagtc acgacgttgt aaaacgacgg ccagtgagcg cgcgtaatac gactcactat agggcgaatt gggtaccggg ccccccctcg aggtcgacgg tatcggggga gctcgcaggg tctccatttt gaagcgggag gtttgaacgc gcagccgcca tgccggggtt ttacgagatt gtgattaagg tccccagcga ccttgacgag catctgcccg gcatttctga cagctttgtg aactgggtgg ccgagaagga atgggagttg ccgccagatt ctgacatgga tctgaatctg attgagcagg cacccctgac cgtggccgag aagctgcagc gcgactttct gacggaatgg cgccgtgtga gtaaggcccc ggaggctctt ttctttgtgc aatttgagaa gggagagagc tacttccaca tgcacgtgct cgtggaaacc accggggtga aatc

[0063] In SEQ ID NO:5, residues 1-1561 of pAAV-RC7 encode the Rep protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19 promoter, and residues 1075-1254 corresponding to the P40 promoter (SEQ ID NO:18)); residues 1578-3791 encode the AAV7 VP1 capsid protein; residues 736-1281 encode a portion of the Rep68 protein; residues 3987-4117 correspond to the AAV2 P5 promoter sequences of SEQ ID NO: 10); residues 4240-4256 are Ml 3 Rev sequences; residues 4264-4280 are Lac operator sequences; 4288-4318 are Lac promoter sequences; residues 4581-5305 correspond to pMB ori sequences, residues 5401-6261 encode an ampicillin resistance determinant; and residues 6262-6360 are bla promoter sequences (Figure 7).

B. Illustrative Non- AAV Helper Function-Providing Polynucleotides

[0064] As used herein, the term“non-AAV helper functions” denotes proteins of Ad, CMV, HSV or other non-AAD viruses (e.g, El a, Elb, E2a, VA and E4) and/or polynucleotides of Ad, CMV, HSV or other non-AAD viruses that are required for the replication and packaging of an rAAV. Such non-AAV helper functions are provided by a“non-AAV helper function-providing polynucleotide,” which as such term is used herein is a virus, plasmid vector, a non-plasmid vector, or a polynucleotide that has been integrated into a cellular chromosome, that provides non-AAV helper functions. The vector, pHelper, and derivatives thereof (such as those commercially available from Cell Biolabs, Inc., Invitrogen, Stratagene and other sources), are suitable non-AAV helper function-providing polynucleotide (see, e.g. , Matsushita, T. el al. (1998)“ Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus f Gene Ther. 5:938-945; Sharma, A. et al. (2010)“Transduction Efficiency Of AAV 2/6, 2/8 And 2/9 Vectors For Delivering Genes In Human Corneal Fibroblasts f Brain Res. Bull. 81(2-3):273-278).

[0065] Plasmid pHelper-Kan (SEQ ID NO:6; Figure 8) is a non-AAV helper function-providing polynucleotide that may be used in accordance with the present invention to provide non-AAV helper functions.

Coding Strand of Plasmid pHelper-Kan (SEQ ID NO:6):

ggtacccaac tccatgctta acagtcccca ggtacagccc accctgcgtc gcaaccagga acagctctac agcttcctgg agcgccactc gccctacttc cgcagccaca gtgcgcagat taggagcgcc acttcttttt gtcacttgaa aaacatgtaa aaataatgta ctaggagaca ctttcaataa aggcaaatgt ttttatttgt acactctcgg gtgattattt accccccacc cttgccgtct gcgccgttta aaaatcaaag gggttctgcc gcgcatcgct atgcgccact ggcagggaca cgttgcgata ctggtgttta gtgctccact taaactcagg cacaaccatc cgcggcagct cggtgaagtt ttcactccac aggctgcgca ccatcaccaa cgcgtttagc aggtcgggcg ccgatatctt gaagtcgcag ttggggcctc cgccctgcgc gcgcgagttg cgatacacag ggttgcagca ctggaacact atcagcgccg ggtggtgcac gctggccagc acgctcttgt cggagatcag atccgcgtcc aggtcctccg cgttgctcag ggcgaacgga gtcaactttg gtagctgcct tcccaaaaag ggtgcatgcc caggctttga gttgcactcg caccgtagtg gcatcagaag gtgaccgtgc ccggtctggg cgttaggata cagcgcctgc atgaaagcct tgatctgctt aaaagccacc tgagcctttg cgccttcaga gaagaacatg ccgcaagact tgccggaaaa ctgattggcc ggacaggccg cgtcatgcac gcagcacctt gcgtcggtgt tggagatctg caccacattt cggccccacc ggttcttcac gatcttggcc ttgctagact gctccttcag cgcgcgctgc ccgttttcgc tcgtcacatc catttcaatc acgtgctcct tatttatcat aatgctcccg tgtagacact taagctcgcc ttcgatctca gcgcagcggt gcagccacaa cgcgcagccc gtgggctcgt ggtgcttgta ggttacctct gcaaacgact gcaggtacgc ctgcaggaat cgccccatca tcgtcacaaa ggtcttgttg ctggtgaagg tcagctgcaa cccgcggtgc tcctcgttta gccaggtctt gcatacggcc gccagagctt ccacttggtc aggcagtagc ttgaagtttg cctttagatc gttatccacg tggtacttgt ccatcaacgc gcgcgcagcc tccatgccct tctcccacgc agacacgatc ggcaggctca gcgggtttat caccgtgctt tcactttccg cttcactgga ctcttccttt tcctcttgcg tccgcatacc ccgcgccact gggtcgtctt cattcagccg ccgcaccgtg cgcttacctc ccttgccgtg cttgattagc accggtgggt tgctgaaacc caccatttgt agcgccacat cttctctttc ttcctcgctg tccacgatca cctctgggga tggcgggcgc tcgggcttgg gagaggggcg cttctttttc tttttggacg caatggccaa atccgccgtc gaggtcgatg gccgcgggct gggtgtgcgc ggcaccagcg catcttgtga cgagtcttct tcgtcctcgg actcgagacg ccgcctcagc cgcttttttg ggggcgcgcg gggaggcggc ggcgacggcg acggggacga cacgtcctcc atggttggtg gacgtcgcgc cgcaccgcgt ccgcgctcgg gggtggtttc gcgctgctcc tcttcccgac tggccatttc cttctcctat aggcagaaaa agatcatgga gtcagtcgag aaggaggaca gcctaaccgc cccctttgag ttcgccacca ccgcctccac cgatgccgcc aacgcgccta ccaccttccc cgtcgaggca cccccgcttg aggaggagga agtgattatc gagcaggacc caggttttgt aagcgaagac gacgaggatc gctcagtacc aacagaggat aaaaagcaag accaggacga cgcagaggca aacgaggaac aagtcgggcg gggggaccaa aggcatggcg actacctaga tgtgggagac gacgtgctgt tgaagcatct gcagcgccag tgcgccatta tctgcgacgc gttgcaagag cgcagcgatg tgcccctcgc catagcggat gtcagccttg cctacgaacg ccacctgttc tcaccgcgcg taccccccaa acgccaagaa aacggcacat gcgagcccaa cccgcgcctc aacttctacc ccgtatttgc cgtgccagag gtgcttgcca cctatcacat ctttttccaa aactgcaaga tacccctatc ctgccgtgcc aaccgcagcc gagcggacaa gcagctggcc ttgcggcagg gcgctgtcat acctgatatc gcctcgctcg acgaagtgcc aaaaatcttt gagggtcttg gacgcgacga gaaacgcgcg gcaaacgctc tgcaacaaga aaacagcgaa aatgaaagtc actgtggagt gctggtggaa cttgagggtg acaacgcgcg cctagccgtg ctgaaacgca gcatcgaggt cacccacttt gcctacccgg cacttaacct accccccaag gttatgagca cagtcatgag cgagctgatc gtgcgccgtg cacgacccct ggagagggat gcaaacttgc aagaacaaac cgaggagggc ctacccgcag ttggcgatga gcagctggcg cgctggcttg agacgcgcga gcctgccgac ttggaggagc gacgcaagct aatgatggcc gcagtgcttg ttaccgtgga gcttgagtgc atgcagcggt tctttgctga cccggagatg cagcgcaagc tagaggaaac gttgcactac acctttcgcc agggctacgt gcgccaggcc tgcaaaattt ccaacgtgga gctctgcaac ctggtctcct accttggaat tttgcacgaa aaccgcctcg ggcaaaacgt gcttcattcc acgctcaagg gcgaggcgcg ccgcgactac gtccgcgact gcgtttactt atttctgtgc tacacctggc aaacggccat gggcgtgtgg cagcaatgcc tggaggagcg caacctaaag gagctgcaga agctgctaaa gcaaaacttg aaggacctat ggacggcctt caacgagcgc tccgtggccg cgcacctggc ggacattatc ttccccgaac gcctgcttaa aaccctgcaa cagggtctgc cagacttcac cagtcaaagc atgttgcaaa actttaggaa ctttatccta gagcgttcag gaattctgcc cgccacctgc tgtgcgcttc ctagcgactt tgtgcccatt aagtaccgtg aatgccctcc gccgctttgg ggtcactgct accttctgca gctagccaac taccttgcct accactccga catcatggaa gacgtgagcg gtgacggcct actggagtgt cactgtcgct gcaacctatg caccccgcac cgctccctgg tctgcaattc gcaactgctt agcgaaagtc aaattatcgg tacctttgag ctgcagggtc cctcgcctga cgaaaagtcc gcggctccgg ggttgaaact cactccgggg ctgtggacgt cggcttacct tcgcaaattt gtacctgagg actaccacgc ccacgagatt aggttctacg aagaccaatc ccgcccgcca aatgcggagc ttaccgcctg cgtcattacc cagggccaca tccttggcca attgcaagcc atcaacaaag cccgccaaga gtttctgcta cgaaagggac ggggggttta cctggacccc cagtccggcg aggagctcaa cccaatcccc ccgccgccgc agccctatca gcagccgcgg gcccttgctt cccaggatgg cacccaaaaa gaagctgcag ctgccgccgc cgccacccac ggacgaggag gaatactggg acagtcaggc agaggaggtt ttggacgagg aggaggagat gatggaagac tgggacagcc tagacgaagc ttccgaggcc gaagaggtgt cagacgaaac accgtcaccc tcggtcgcat tcccctcgcc ggcgccccag aaattggcaa ccgttcccag catcgctaca acctccgctc ctcaggcgcc gccggcactg cctgttcgcc gacccaaccg tagatgggac accactggaa ccagggccgg taagtctaag cagccgccgc cgttagccca agagcaacaa cagcgccaag gctaccgctc gtggcgcggg cacaagaacg ccatagttgc ttgcttgcaa gactgtgggg gcaacatctc cttcgcccgc cgctttcttc tctaccatca cggcgtggcc ttcccccgta acatcctgca ttactaccgt catctctaca gcccctactg caccggcggc agcggcagcg gcagcaacag cagcggtcac acagaagcaa aggcgaccgg atagcaagac tctgacaaag cccaagaaat ccacagcggc ggcagcagca ggaggaggag cgctgcgtct ggcgcccaac gaacccgtat cgacccgcga gcttagaaat aggatttttc ccactctgta tgctatattt caacaaagca ggggccaaga acaagagctg aaaataaaaa acaggtctct gcgctccctc acccgcagct gcctgtatca caaaagcgaa gatcagcttc ggcgcacgct ggaagacgcg gaggctctct tcagcaaata ctgcgcgctg actcttaagg actagtttcg cgccctttct caaatttaag cgcgaaaact acgtcatctc cagcggccac acccggcgcc agcacctgtc gtcagcgcca ttatgagcaa ggaaattccc acgccctaca tgtggagtta ccagccacaa atgggacttg cggctggagc tgcccaagac tactcaaccc gaataaacta catgagcgcg ggaccccaca tgatatcccg ggtcaacgga atccgcgccc accgaaaccg aattctcctc gaacaggcgg ctattaccac cacacctcgt aataacctta atccccgtag ttggcccgct gccctggtgt accaggaaag tcccgctccc accactgtgg tacttcccag agacgcccag gccgaagttc agatgactaa ctcaggggcg cagcttgcgg gcggctttcg tcacagggtg cggtcgcccg ggcgttttag ggcggagtaa cttgcatgta ttgggaattg tagttttttt aaaatgggaa gtgacgtatc gtgggaaaac ggaagtgaag atttgaggaa gttgtgggtt ttttggcttt cgtttctggg cgtaggttcg cgtgcggttt tctgggtgtt ttttgtggac tttaaccgtt acgtcatttt ttagtcctat atatactcgc tctgtacttg gcccttttta cactgtgact gattgagctg gtgccgtgtc gagtggtgtt ttttaatagg tttttttact ggtaaggctg actgttatgg ctgccgctgt ggaagcgctg tatgttgttc tggagcggga gggtgctatt ttgcctaggc aggagggttt ttcaggtgtt tatgtgtttt tctctcctat taattttgtt atacctccta tgggggctgt aatgttgtct ctacgcctgc gggtatgtat tcccccgggc tatttcggtc gctttttagc actgaccgat gttaaccaac ctgatgtgtt taccgagtct tacattatga ctccggacat gaccgaggaa ctgtcggtgg tgctttttaa tcacggtgac cagttttttt acggtcacgc cggcatggcc gtagtccgtc ttatgcttat aagggttgtt tttcctgttg taagacaggc ttctaatgtt taaatgtttt tttttttgtt attttatttt gtgtttaatg caggaacccg cagacatgtt tgagagaaaa atggtgtctt tttctgtggt ggttccggaa cttacctgcc tttatctgca tgagcatgac tacgatgtgc ttgctttttt gcgcgaggct ttgcctgatt ttttgagcag caccttgcat tttatatcgc cgcccatgca acaagcttac ataggggcta cgctggttag catagctccg agtatgcgtg tcataatcag tgtgggttct tttgtcatgg ttcctggcgg ggaagtggcc gcgctggtcc gtgcagacct gcacgattat gttcagctgg ccctgcgaag ggacctacgg gatcgcggta tttttgttaa tgttccgctt ttgaatctta tacaggtctg tgaggaacct gaatttttgc aatcatgatt cgctgcttga ggctgaaggt ggagggcgct ctggagcaga tttttacaat ggccggactt aatattcggg atttgcttag agacatattg ataaggtggc gagatgaaaa ttatttgggc atggttgaag gtgctggaat gtttatagag gagattcacc ctgaagggtt tagcctttac gtccacttgg acgtgagggc agtttgcctt ttggaagcca ttgtgcaaca tcttacaaat gccattatct gttctttggc tgtagagttt gaccacgcca ccggagggga gcgcgttcac ttaatagatc ttcattttga ggttttggat aatcttttgg aataaaaaaa aaaaaacatg gttcttccag ctcttcccgc tcctcccgtg tgtgactcgc agaacgaatg tgtaggttgg ctgggtgtgg cttattctgc ggtggtggat gttatcaggg cagcggcgca tgaaggagtt tacatagaac ccgaagccag ggggcgcctg gatgctttga gagagtggat atactacaac tactacacag agcgagctaa gcgacgagac cggagacgca gatctgtttg tcacgcccgc acctggtttt gcttcaggaa atatgactac gtccggcgtt ccatttggca tgacactacg accaacacga tctcggttgt ctcggcgcac tccgtacagt agggatcgcc tacctccttt tgagacagag acccgcgcta ccatactgga ggatcatccg ctgctgcccg aatgtaacac tttgacaatg cacaacgtga gttacgtgcg aggtcttccc tgcagtgtgg gatttacgct gattcaggaa tgggttgttc cctgggatat ggttctgacg cgggaggagc ttgtaatcct gaggaagtgt atgcacgtgt gcctgtgttg tgccaacatt gatatcatga cgagcatgat gatccatggt tacgagtcct gggctctcca ctgtcattgt tccagtcccg gttccctgca gtgcatagcc ggcgggcagg ttttggccag ctggtttagg atggtggtgg atggcgccat gtttaatcag aggtttatat ggtaccggga ggtggtgaat tacaacatgc caaaagaggt aatgtttatg tccagcgtgt ttatgagggg tcgccactta atctacctgc gcttgtggta tgatggccac gtgggttctg tggtccccgc catgagcttt ggatacagcg ccttgcactg tgggattttg aacaatattg tggtgctgtg ctgcagttac tgtgctgatt taagtgagat cagggtgcgc tgctgtgccc ggaggacaag gcgtctcatg ctgcgggcgg tgcgaatcat cgctgaggag accactgcca tgttgtattc ctgcaggacg gagcggcggc ggcagcagtt tattcgcgcg ctgctgcagc accaccgccc tatcctgatg cacgattatg actctacccc catgtaggcg tggacttccc cttcgccgcc cgttgagcaa ccgcaagttg gacagcagcc tgtggctcag cagctggaca gcgacatgaa cttaagcgag ctgcccgggg agtttattaa tatcactgat gagcgtttgg ctcgacagga aaccgtgtgg aatataacac ctaagaatat gtctgttacc catgatatga tgctttttaa ggccagccgg ggagaaagga ctgtgtactc tgtgtgttgg gagggaggtg gcaggttgaa tactagggtt ctgtgagttt gattaaggta cggtgatcaa tataagctat gtggtggtgg ggctatacta ctgaatgaaa aatgacttga aattttctgc aattgaaaaa taaacacgtt gaaacataac atgcaacagg ttcacgattc tttattcctg ggcaatgtag gagaaggtgt aagagttggt agcaaaagtt tcagtggtgt attttccact ttcccaggac catgtaaaag acatagagta agtgcttacc tcgctagttt ctgtggattc actagaatcg atgtaggatg ttgcccctcc tgacgcggta ggagaagggg agggtgccct gcatgtctgc cgctgctctt gctcttgccg ctgctgagga ggggggcgca tctgccgcag caccggatgc atctgggaaa agcaaaaaag gggctcgtcc ctgtttccgg aggaatttgc aagcggggtc ttgcatgacg gggaggcaaa cccccgttcg ccgcagtccg gccggcccga gactcgaacc gggggtcctg cgactcaacc cttggaaaat aaccctccgg ctacagggag cgagccactt aatgctttcg ctttccagcc taaccgctta cgccgcgcgc ggccagtggc caaaaaagct agcgcagcag ccgccgcgcc tggaaggaag ccaaaaggag cgctcccccg ttgtctgacg tcgcacacct gggttcgaca cgcgggcggt aaccgcatgg atcacggcgg acggccggat ccggggttcg aaccccggtc gtccgccatg atacccttgc gaatttatcc accagaccac ggaagagtgc ccgcttacag gctctccttt tgcacggtct agagcgtcaa cgactgcgca cgcctcaccg gccagagcgt cccgaccatg gagcactttt tgccgctgcg caacatctgg aaccgcgtcc gcgactttcc gcgcgcctcc accaccgccg ccggcatcac ctggatgtcc aggtacatct acggattacg tcgacgttta aaccatatga tcagctcact caaaggcggt aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggtctgaca gtcagaagaa ctcgtcaaga aggcgataga aggcgatgcg ctgcgaatcg ggagcggcga taccgtaaag cacgaggaag cggtcagccc attcgccgcc aagctcttca gcaatatcac gggtagccaa cgctatgtcc tgatagcggt ccgccacacc cagccggcca cagtcgatga atccagaaaa gcggccattt tccaccatga tattcggcaa gcaggcatcg ccatgggtca cgacgagatc ctcgccgtcg ggcatgctcg ccttgagcct ggcgaacagt tcggctggcg cgagcccctg atgctcttcg tccagatcat cctgatcgac aagaccggct tccatccgag tacgtgctcg ctcgatgcga tgtttcgctt ggtggtcgaa tgggcaggta gccggatcaa gcgtatgcag ccgccgcatt gcatcagcca tgatggatac tttctcggca ggagcaaggt gagatgacag gagatcctgc cccggcactt cgcccaatag cagccagtcc cttcccgctt cagtgacaac gtcgagtaca gctgcgcaag gaacgcccgt cgtggccagc cacgatagcc gcgctgcctc gtcttgcagt tcattcaggg caccggacag gtcggtcttg acaaaaagaa ccgggcgccc ctgcgctgac agccggaaca cggcggcatc agagcagccg attgtctgtt gtgcccagtc atagccgaat agcctctcca cccaagcggc cggagaacct gcgtgcaatc catcttgttc aatcatactc ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctaaat tgtaagcgtt aatattttgt taaaattcgc gttaaatttt tgttaaatca gctcattttt taaccaatag gccgaaatcg gcaaaatccc ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag tccactatta aagaacgtgg actccaacgt caaagggcga aaaaccgtct atcagggcga tggcccacta cgtgaaccat caccctaatc aagttttttg gggtcgaggt gccgtaaagc actaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa cgtggcgaga aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt agcggtcacg ctgcgcgtaa ccaccacacc cgccgcgctt aatgcgccgc tacagggcgc gatggatcc

[0066] In SEQ ID NO:6, residues 1-5343 of pHelper-Kan are derived from adenovirus, and include a polynucleotide encoding the E2A protein (residues 258- 1847); residues 5344-8535 are derived from adenovirus, and include a polynucleotide encoding the E4orf6 protein; residues 9423-10011 correspond to ori sequences; residues 10182-10976 encode a kanamycin resistance determinant expressed by a bla promoter sequence (residues 10977-11081); residues 11107-11561 correspond to fl ori sequences (Figure 8).

C. Illustrative rAAV Plasmid Vectors

[0067] As discussed above, AAV helper function-providing polynucleotides and non-AAV helper function-providing polynucleotides are typically employed in conceit with an rAAV plasmid vector to comprise a triple plasmid transfection system. Multiple commercially available rAAV plasmid vectors ( e.g ., pAV-CMV-EGFP, pGOI, etc. (Cell Biolabs, Inc., Invitrogen and Stratagene)) may be used in accordance with the present invention. An illustrative rAAV plasmid vector that may be used in accordance with the present invention is pAV-CMV-EGFP (SEQ ID NO:7; Figure 9) which comprises a 5’ ITR, a U6 promoter, CMV enhancer and promoter sequences, a polynucleotide encoding the enhanced green fluorescent protein (EGFP) (Gambotto, A. el al. (2000)“ Immunogenicity Of Enhanced Green Fluorescent Protein (EGFP) In BALB/C Mice: Identification Of An H2-Kd-Restricted CTL Epitope ,” Gene Ther. 7(23):2036-2040; Tsien, R.Y. (1998)“The Green Fluorescent Protein ,” Annu. Rev. Biochem. 67:509-544; Cinelli, R.A. et al. (2000)“ The Enhanced Green Fluorescent Protein As A Tool For The Analysis Of Protein Dynamics And Localization: Local Fluorescence Study At The Single-Molecule Level f Photochem. Photobiol. 71(6):771- 776; Chopra A. (2008)“ Recombinant Adenovirus With Enhanced Green Fluorescent Proteinf In: MOLECULAR IMAGING AND CONTRAST AGENT DATABASE (MICAD), National Center for Biotechnology Information, Bethesda MD), FLAG-tag and 6xHis- tag sites for facilitating recovery or localization of expressed proteins, an SV40 poly(A) site and a 3’ ITR.

Coding Strand of Plasmid pAV-CMV-EGFP (SEQ ID NO:7):

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt ggtcgcccgg ccctccagtg agcgagcgcg cagagaggga gtggccaact ccatcactag gggttcctgc ggccgcacgc gtctagttat taatagtaat cgaattcgtg ttactcataa ctagtaaggt cgggcaggaa gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag ataattagaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat atgcttaccg taacttgaaa gtatttcgat ttcttgggtt tatatatctt gtggaaagga cgcgggatcc actggaccag gcagcagcgt cagaagactt ttttggaaaa gcttgactag taatactgta atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttgcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagagatc cggtaccgag gagatctgcc gccgcgatcg ccggcgcgcc agatctcacg cttaactagc tagcggaccg acgcgtacgc ggccgctcga gatggtgagc aagggcgagg agctgttcac cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt tcatctgcac caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa cgtctatatc atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca cccccatcgg cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtccg ccctgagcaa agaccccaac gagaagcgcg atcacatggt cctgctggag ttcgtgaccg ccgccgggat cactctcggc atggacgagc tgtacaagta agtcgaggat tataaggatg acgacgataa attcgtcgag caccaccacc accaccacta ataaggttta tccgatccac cggatctaga taagatatcc gatccaccgg atctagataa ctgatcataa tcagccatac cacatttgta gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa acataaaatg aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta acgcggtaac cacgtgcgga ccgagcggcc gcaggaaccc ctagtgatgg agttggccac tccctctctg cgcgctcgct cgctcactga ggccgggcga ccaaaggtcg cccgacgccc gggctttgcc cgggcggcct cagtgagcga gcgagcgcgc agctgcctgc aggggcgcct gatgcggtat tttctcctta cgcatctgtg cggtatttca caccgcatac gtcaaagcaa ccatagtacg cgccctgtag cggcgcatta agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta cacctgccag cgccttagcg cccgctcctt tcgctttctt cccttccttt ctcgccacgt tcgccggctt tccccgtcaa gctctaaatc gggggctccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg atttgggtga tggttcacgt agtgggccat cgccctgata gacggttttt cgccctttga cgttggagtc cacgttcttt aatagtggac tcttgttcca aactggaaca acactcaacc ctatctcggg ctattctttt gatttataag ggattttgcc gatttcggcc tattggttaa aaaatgagct gatttaacaa aaatttaacg cgaattttaa caaaatatta acgtttacaa ttttatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc cagccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag acgaaagggc ctcgtgatac gcctattttt ataggttaat gtcatgataa taatggtttc ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt gtcgccctta ttcccttttt tgcggcattt tgccttcctg tttttgctca cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc cataaccatg agtgataaca ctgcggccaa cttacttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt gctcacatgt

[0068] In SEQ ID NO:7, residues 1-128 of pAV-CMV-EGFP correspond to the 5’ ITR; residues 201-441 are U6 promoter sequences; residues 562-865 are human cytomegalovirus (CMV) immediate early enhancer sequences; residues 866-1068 comprise the CMV immediate early promoter; residues 1192-1911 comprise a mammalian codon-optimized polynucleotide that encodes the EGFP; residues 1918- 1941 encode the FLAG-tag; residues 1951-1968 encode the 6xHis-tag; residues 2139- 2260 encode the SV40 poly(A) sequence; residues 2293-2433 correspond to the 3’ ITR; residues 2508-22963 correspond to FI ori sequences; residues 3350-4210 encode an ampicillin resistance determinant and its signal sequence (residues 3350-3418) expressed by a bla promoter sequence (residues 3245-3349); residues 4381-4969 correspond to an ori sequence (Figure 9).

[0069] A second illustrative rAAV plasmid vector that may be used in accordance with the present invention is pAV-TBG-EGFP (SEQ ID NO:8; Figure 10) which comprises a 5’ ITR, a thyroid hormone-binding globulin (TBG) promoter, a polynucleotide encoding the enhanced green fluorescent protein (EGFP), FLAG-tag and 6xHis-tag sites for facilitating recovery or localization of expressed proteins, an SV40 poly(A) site and a 3’ ITR.

Coding Strand of Plasmid pAV-TBG-EGFP (SEQ ID NO:8):

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact aggggttcct gcggccggtc gcgtctagta ctagtaggtt aatttttaaa aagcagtcaa aagtccaagt ggcccttggc agcatttact ctctctgttt gctctggtta ataatctcag gagcacaaac attccagatc caggttaatt tttaaaaagc agtcaaaagt ccaagtggcc cttggcagca tttactctct ctgtttgctc tggttaataa tctcaggagc acaaacattc cagatccggc gcgccagggc tggaagctac ctttgacatc atttcctctg cgaatgcatg tataatttct acagaaccta ttagaaagga tcacccagcc tctgcttttg tacaactttc ccttaaaaaa ctgccaattc cactgctgtt tggcccaata gtgagaactt tttcctgctg cctcttggtg cttttgccta tggcccctat tctgcctgct gaagacactc ttgccagcat ggacttaaac ccctccagct ctgacaatcc tctttctctt ttgttttaca tgaagggtct ggcagccaaa gcaatcactc aaagttcaaa ccttatcatt ttttgctttg ttcctcttgg ccttggtttt gtacatcagc tttgaaaata ccatcccagg gttaatgctg gggttaattt ataactaaga gtgctctagt tttgcaatac aggacatgct ataaaaatgg aaagatgttg ctttctgaga gacaggtacc gaggagatct gccgccgcga tcgccaccat ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc atcctggtcg agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg ccacttacgg caagctgacc ctgaagttca tctgcaccac cggcaagctg cccgtgccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc taccccgacc acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc caggagcgca ccatcttctt caaggacgac ggcaactaca agacccgcgc cgaggtgaag ttcgagggcg acaccctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac ggcaacatcc tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg gccgacaagc agaagaacgg catcaaggtg aacttcaaga tccgccacaa catcgaggac ggcagcgtgc agctcgccga ccactaccag cagaacaccc ccatcggcga cggccccgtg ctgctgcccg acaaccacta cctgagcacc cagtccgccc tgagcaaaga ccccaacgag aagcgcgatc acatggtcct gctggagttc gtgaccgccg ccgggatcac tctcggcatg gacgagctgt acaagtagac gcgtacgcgg ccgctcgagg attataagga tgacgacgat aaattcgtcg agcaccacca ccaccaccac taataaggtt tatccgatcc accggatcta gataagatat ccgatccacc ggatctagat aactgatcat aatcagccat accacatttg tagaggtttt acttgcttta aaaaacctcc cacacctccc cctgaacctg aaacataaaa tgaatgcaat tgttgttgtt aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct taacgcggta accacgtgcg gacccaacgg ccgcaggaac ccctagtgat ggagttggcc actccctctc tgcgcgctcg ctcgctcact gaggccgggc gaccaaaggt cgcccgacgc ccgggctttg cccgggcggc ctcagtgagc gagcgagcgc gcagctgcct gcaggggcgc ctgatgcggt attttctcct tacgcatctg tgcggtattt cacaccgcat acgtcaaagc aaccatagta cgcgccctgt agcggcacat taagcgcggc gggtgtggtg gttacgcgca gcgtgaccgc tacacctgcc agcgccttag cgcccgctcc tttcgctttc ttcccttcct ttctcgccac gttcgccggc tttccccgtc aagctctaaa tcgggggctc cctttagggt tccgatttag tgctttacgg cacctcgacc ccaaaaaact tgatttgggt gatggttcac gtagtgggcc atcgccctga tagacggttt ttcgcccttt gacgttggag tccacgttct ttaatagtgg actcttgttc caaactggaa caacactcaa ctctatctcg ggctattctt ttgatttata agggattttg ccgatttcgg tctattggtt aaaaaatgag ctgatttaac aaaaatttaa cgcgaatttt aacaaaatat taacgtttac aattttatgg tgcactctca gtacaatctg ctctgatgcc gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg acgggcttgt ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg gcctcgtgat acgcctattt ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct gccataacca tgagtgataa cactgcggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt catttttaat ttaaaaggat ctaggtgaag atcctttttg ataatctcat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtt cttctagtgt agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac gcttcccgaa gggagaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt ttgctcacat gt

[0070] In SEQ ID NO:8, residues 1-130 of pAV-TBG-EGFP correspond to the 5’ ITR; residues 150-854 are TBG promoter sequences, with residues 415-824 comprising the TBG promoter; residues 886-1608 encode the EGFP; residues 1630-1653 encode the FLAG-tag; residues 1663-1680 encode the 6xHis-tag; residues 1851-1972 encode the poly(A) sequence; residues 2005-2145 corresponds to the 3’ ITR; residues 2220- 2675 correspond to FI ori sequences; residues 3062-3922 encode an ampicillin resistance determinant and its signal sequence (residues 3062-3130) expressed by a bla promoter sequence (residues 2957-3061); residues 4093-4681 correspond to an ori sequence (Figure 10).

[0071] As used herein, the term“native AAV serotype promoter sequence” is intended to denote a promoter sequence that natively controls the transcription of an AAV rep gene or is natively present within such rep gene. For example:

• AAV 1 P5 promoter sequences natively control the transcription of the rep gene of AAV1 and AAV1 P40 promoter sequences are natively found within the rep gene of AAV 1. Thus, the AAV 1 P5 promoter sequences and the AAV 1 P40 promoter sequences are native AAV serotype promoter sequences of the rep gene of AAV 1 ;

• AAV2 P5 promoter sequences natively control the transcription of the rep gene of AAV2 and the AAV2 P40 promoter sequences are natively found within the rep gene of AAV2. Thus, the AAV2 P5 promoter sequences and the AAV2 P40 promoter sequences are native AAV serotype promoter sequences of the rep gene of AAV2;

• AAV5 P5 promoter sequences natively control the transcription of the rep gene of AAV5 and the AAV5 P40 promoter sequences are natively found within the rep gene of AAV5. Thus, the AAV5 P5 promoter sequences and the AAV5 P40 promoter sequences are native AAV serotype promoter sequences of the rep gene of AAV5;

• AAV6 P5 promoter sequences natively control the transcription of the rep gene of AAV6 and the AAV6 P40 promoter sequences are natively found within the rep gene of AAV6. Thus, the AAV6 P5 promoter sequences and the AAV6 P40 promoter sequences are native AAV serotype promoter sequences of the rep gene of AAV6; and

• AAV7 P5 promoter sequences natively control the transcription of the rep gene of AAV7 and the AAV7 P40 promoter sequences are natively found within the rep gene of AAV7. Thus, the AAV7 P5 promoter sequences and the AAV7 P40 promoter sequences are native AAV serotype promoter sequences of the rep gene of AAV7;

[0072] Native AAV P5 and P40 promoter sequences for AAV serotypes 1-8 are shown in Table 1. Such sequences, or subsequences thereof that are capable of mediating transcription, may be used in accordance with the methods of the present invention.

[0073] In contrast, the term“non-native AAV serotype promoter sequence” is intended to denote a promoter sequence that does not natively control a rep gene of an AAV and is not natively found within such rep gene. Illustrative, non-limiting examples of non-native AAV serotype promoter sequences include: the AAV1 P5 promoter when used to direct the expression of an AAV2, AAV5, AAV6, or AAV7 rep gene; the AAV2 P5 promoter when used to direct the expression of an AAV1, AAV5, AAV6, or AAV7 rep gene; the AAV5 P5 promoter when used to direct the expression of an AAV1, AAV2, AAV6, or AAV7 rep gene; the AAV6 P5 promoter when used to direct the expression of an AAV1, AAV2, AAV5, or AAV7 rep gene; the AAV7 P5 promoter when used to direct the expression of an AAV1, AAV2, AAV5, or AAV6 rep gene; the AAVl P40 promoter, when present within an AAV2, AAV5, AAV6, or AAV7 rep gene; the AAV2 P40 promoter, when present within an AAVl, AAV5, AAV6, or AAV7 rep gene; the AAV5 P40 promoter, when present within an AAVl, AAV2, AAV6, or AAV7 rep gene; the AAV6 P40 promoter, when present within an AAV1, AAV2, AAV5, or AAV7 rep gene; the AAV7 P40 promoter, when present within an AAV1, AAV2, AAV5, or AAV6 rep gene, etc.

[0074] In one embodiment, one or more of such AAV serotype promoter sequences can be genetically engineered into recombinant AAV helper plasmids that are designed to provide the Rep and Cap proteins to replace or augment the existing P5 or P40 promoters of such plasmids. Such modification is preferably accomplished using well- known methods of recombinant DNA technology.

[0075] The identity of the serotype of promoter sequences is indicated herein by denoting the involved promoter ( e.g ., P5, P40, etc.), the serotype of the rep gene with which it is natively associated, and the name of the vector. Thus, for example, a pAAV- RC2 plasmid that comprises a P5 promoter sequence that is natively associated with AAV2 is denoted as P5(2)-RC2; a pAAV-RC2 plasmid that comprises a P5 promoter sequence that is natively associated with AAV3 is denoted as P5(3)-RC2; a pAAV- RC5 plasmid that comprises a P40 promoter sequence that is natively associated with AAV7 is denoted as P40(7)-RC5; a pAAV-RC2 plasmid that comprises a P5 promoter sequence that is natively associated with AAV3 and a P40 promoter sequence that is natively associated with AAV8 is denoted as P5(3)/P40(8)-RC2; etc.

[0076] In one embodiment, the introduced AAV serotype promoter sequence will replace an initially present AAV serotype promoter sequence. In other embodiments, the introduced AAV serotype promoter sequence will be present in addition to such initially present AAV serotype promoter sequence, and will be positioned 5’ to, or 3’ to, such initially present AAV serotype promoter sequence. The introduced nucleotide sequence may be positioned adjacent to, or apart from, such initially present AAV serotype promoter sequence.

[0077] The substitution or addition of one or more of such AAV serotype promoter sequences invention increases rAAV production titers. As used herein, the term “production titer” is intended to denote the amount of concentration of infectious rAAV in a preparation. Such amounts or concentrations are preferably determined by titering the AAV or rAAV in such preparation. The production titers of the rAAV preparations of the present invention are preferably titered after subjecting producing cells ( e.g ., HEK293 transformed with an rAAV plasmid vector, an AAV helper vector providing Rep and Cap proteins, and an Ad helper vector providing required adenovirus transcription and translation factors) to three rounds of freeze / thawing, followed by sonication to release the rAAV particles. The preparation is then centrifuged. The employed AAV helper vector is localized to the supernatant. An aliquot of the preparation is treated with proteinase K, and the number of AAV genomes is determined. An aliquot of the preparation is infected into HeLa-32C2 cells (which express AAV2 Rep and Cap proteins), and infectious titer is measured using the infectious center assay (ICA) (Franqois, A. et al. (2018) “ Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls ,” Molec. Ther. Meth. Clin. Develop. 10:223-236) or more preferably, as the median tissue culture infective dose (TCID50) (Zen, Z. et al. (2004)“ Infectious Titer Assay For Adeno-Associated Virus Vectors With Sensitivity Sufficient To Detect Single Infectious Events ,” Hum. Gene Ther. 15:709-715).

[0078] As used herein, an rAAV production titer is said to be“increased” by the methods of the present invention if the production titer obtained from the use of the methods of the present invention is at least 10% greater, more preferably at least 20% greater, still more preferably at least 30% greater, still more preferably at least 40% greater, still more preferably at least 50% greater, still more preferably at least 60% greater, still more preferably at least 70% greater, still more preferably at least 80% greater, still more preferably at least 90% greater, still more preferably at least 2-fold greater, still more preferably at least 110% greater, still more preferably at least 120% greater, still more preferably at least 130% greater, still more preferably at least 140% greater, still more preferably at least 2.5-fold greater, still more preferably at least 160% greater, still more preferably at least 170% greater, still more preferably at least 180% greater, still more preferably at least 190% greater, and still more preferably at least 3- fold greater than the titer obtained from a similarly conducted production in which the additionally provided ions were not provided.

[0079] The rAAV whose production titer may be increased using the methods of the present invention may comprise any transgene cassette that permits the rAAV to be packaged into an rAAV plasmid vector that may be encapsidated within an AAV capsid particle. Without limitation, such transgene cassette(s) may be of human, primate (including chimpanzee, gibbon, gorilla, orangutan, etc), cercopithecine (including baboon, cynomolgus monkey, velvet monkey, etc), canine, glirine (including rat, mouse, hamster, guinea pig, etc) , feline, ovine, caprine, or equine origin.

[0080] In preferred embodiments, such an rAAV or rAAV plasmid vector will encode a protein ( e.g ., an enzyme, hormone, antibody, receptor, ligand, etc), or comprise a transcribed nucleic acid, that is relevant to a genetic or heritable disease or condition, such that it may be used in gene therapy to treat such disease or condition.

[0081] The methods of the present invention may be used to increase the production titer of rAAV and rAAV plasmid vectors in cells that have been additionally transfected with:

(1) an AAD helper vector possessing a non-native AAV serotype promoter sequence and capable of expressing proteins or RNA molecules that are not natively provided by such rAAV or rAAV plasmid vectors, but are required for their production. As discussed above, such proteins or RNA molecules include the genes encoding the Rep52 and Rep78 proteins that are required for vector transcription control and replication, and for the packaging of viral genomes into the viral capsule, and cap genes that encode VP capsid proteins required to form infectious particles; and

(2) an Ad helper vector that can provide the non- AAV helper proteins (e.g., El a, Elb, E2a, VA and E4) or RNA molecules that are not provided by such rAAV or rAAV plasmid vectors, but are required for their production.

[0082] In one embodiment for producing the rAAV of the present invention, all of such genes and RNA molecules are provided on the same helper virus (or more preferably, helper vector) so as to comprise, in concert with an rAAV, a double plasmid transfection system. More preferably, however, for producing the rAAV of the present invention, the AAV helper function-providing polynucleotide that provides the required rep and cap genes and such non-native AAV serotype promoter sequences are provided on a vector that is separate from the vector that comprises the non- AAV helper function providing polynucleotide, so that such vectors or plasmids, in concert with the rAAV, comprise a triple plasmid transfection system. [0083] The invention thus derives in part from the recognition that the production of rAAV may be increased by causing the expression of Rep and Cap proteins to be directed by promoter sequences that are not native promoter sequences. Thus, by modifying a particular rAAV to replace its native P5 and/or P40 AAV serotype promoter sequence(s) with a non-native P5 and/or P40 AAV serotype promoter sequence (or by incorporating a non-native P5 and/or P40 AAV serotype promoter sequence into such rAAV), the methods of the present invention may be employed to increase the production titer of rAAV belonging to any serotype, including the AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, AAV9 and AAV10 serotypes, and including hybrid serotypes ( e.g ., AAV2/5 and rAAV2/5, which is a hybrid of AAV serotypes 2 and 5 and thus has the trophism of both such serotypes).

[0084] The methods of the present invention may be employed to increase the production titers of rAAV that are to be produced using“helper” RNA or proteins provided by an adenovirus, a herpes simplex virus, a cytomegalovirus, a vaccinia virus or a papillomavirus.

[0085] The methods of the present invention may be employed to increase the production titers of rAAV produced by cells in adherent monolayer culture or in suspension culture, and may be used with any method capable of producing rAAV. Preferably, however, rAAV is produced by transfecting baby hamster kidney (BHK) cells, or more preferably, human embryonic kidney (HEK) cells grown in tissue culture with the plasmid vectors described above. The BHK cell line BHK-21 (ATCC CCL- 10), which lacks endogenous retroviruses is a preferred BHK cell line. The HEK cell line HEK293 (ATCC CRL-1573) and its derivatives, such as HEK293T (ATCC CRL- 3216, which is a highly transfectable derivative of the HEK293 cell line into which the temperature-sensitive gene for SV40 T-antigen was inserted) or HEK293T/17 (ATCC® CRL-11268, which was selected for its ease of transfection) are particularly preferred. The HEK293T/17 SF cell line (ATCC ACS-4500) is a derivative of the 293T/17 cell line (ATCC CRL-11268), adapted to serum-free medium and suspension, and may be employed if desired.

[0086] The preferred base medium of the present invention for culturing such cells is Eagle’s Minimum Essential Medium (ATCC Catalog No. 30-2003) or Dulbecco’s Modified Eagle’s Medium (DMEM; Mediatech, Manassas, VA). Fetal bovine serum ( e.g ., FBS; HyClone Laboratories, South Logan, UT) is added to a final concentration of 10% in order to make the complete growth medium. Eagle’s Minimum Essential Medium and Dulbecco’s Modified Eagle’s Medium are complex media that contain amino acids, vitamins, and optionally glucose, in addition to various inorganic salts. The media differ in that Dulbecco's modified Eagle's medium contains approximately four times as much of the vitamins and amino acids present in the original formula of Eagle’s Minimum Essential Medium, and two to four times as much glucose. Additionally, it contains iron in the form of ferric sulfate and phenol red for pH indication (Yao, T et al. (2017)“ Animal-Cell Culture Media: History, Characteristics, And Current Issues,” Reproduc. Med. Biol. 16(2): 99-117).

[0087] Cells to be used for such transfection are preferably passaged twice weekly to maintain them in exponential growth phase. For small-scale transfections, an aliquot of, for example, 1 x 10 ⁶ HEK293 or BHK cells per well on a multi-well plate, or 1.5 x 10 ⁷ HEK293 cells per 15-cm dish, may be employed. For large-scale production HEK293 or BHK cells may be collected from multiple confluent 15-cm plates, and split into two 10-layer cell stacks (Corning, Corning, NY) containing 1 liter of complete culturing medium. In one embodiment, such cells are grown for 4 days in such medium before transfection. The day before transfection, the two cell stacks may be trypsinized and the cells (e.g., approximately 6 x 10 ⁸ cells) may be resuspended in 200 ml of medium. Preferably, the cells are allowed to attach for 24 hours before transfection. Confluency of the cell stacks may be monitored using a Diaphot inverted microscope (Nikon, Melville, NY) from which the phase-contrast hardware had been removed in order to accommodate the cell stack on the microscope stage.

[0088] In particular, the present invention thus provides a method for increasing the production titer of a recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV;

(2) a recombinantly-modified adeno-associated virus (AAV) helper vector that comprises an AAV helper function-providing polynucleotide, wherein such polynucleotide comprises a non-native AAV serotype P5 or P40 promoter sequence in replacement of, or in addition to, a native AAV serotype promoter sequence; and

(3) a vector that comprises a non-AAV helper function-providing polynucleotide;

wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV, and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

[0089] The present invention further provides a method for increasing the production titer of a recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV; and

(2) a recombinantly-modified adeno-associated virus (AAV) helper vector that comprises:

(a) an AAV helper function-providing polynucleotide, wherein such polynucleotide comprises a non-native AAV serotype P5 or P40 promoter sequence in replacement of, or in addition to, a native AAV serotype promoter sequence; and

(b) a non-AAV helper function-providing polynucleotide;

wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV, and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

[0090] In preferred embodiments, the transgene cassette of such rAAV encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition. II. Pharmaceutical Compositions of the Present Invention

[0091] The invention additionally includes pharmaceutical compositions that comprise a pharmaceutically acceptable preparation of rAAV produced in accordance with the methods of the present invention, and a pharmaceutically acceptable carrier. The rAAV of such pharmaceutical compositions comprises a transgene cassette that encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition, and is present in such pharmaceutical composition in an amount effective to (“effective amount”)

[0092] The term“pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term“carrier” refers to a diluent, adjuvant ( e.g ., Freund’s adjuvant complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Suitable pharmaceutical excipients are described in US Patents No. 8,852,607; 8,192,975; 6,764,845; 6,759,050; and 7,598,070.

[0093] Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate, or as an aqueous solution in a hermetically sealed container such as a vial, an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline, or other diluent can be provided so that the ingredients may be mixed prior to administration.

[0094] The invention also provides a pharmaceutical pack or kit comprising one or more containers such pharmaceutical composition. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0095] The rAAV of such pharmaceutical compositions is preferably packaged in a hermetically sealed container, such as a vial, an ampoule or sachette indicating the quantity of the molecule, and optionally including instructions for use. In one embodiment, the rAAV of such kit is supplied as a dry sterilized lyophilized powder or water-free concentrate in a hermetically sealed container and can be reconstituted, e.g ., with water, saline, or other diluent to the appropriate concentration for administration to a subject. The lyophilized material should be stored at between 2°C and 8°C in their original container and the material should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In another embodiment, the rAAV of such kit is supplied as an aqueous solution in a hermetically sealed container and can be diluted, e.g. , with water, saline, or other diluent, to the appropriate concentration for administration to a subject. The kit can further comprise one or more other prophylactic and/or therapeutic agents useful for the treatment of the disease or condition, in one or more containers; and/or the kit can further comprise one or more cytotoxic antibodies that bind one or more cancer antigens associated with cancer. In certain embodiments, the other prophylactic or therapeutic agent is a chemotherapeutic. In other embodiments, the prophylactic or therapeutic agent is a biological or hormonal therapeutic.

III. Uses of the Invention

[0096] The methods of the present invention may be used to facilitate the production of rAAV, and may particularly be used to facilitate the production of rAAV that comprise transgene cassettes that encode a protein (e.g., an enzyme, hormone, antibody, receptor, ligand, etc.), or of rAAV that comprise a transcribed nucleic acid, that is relevant to a genetic or heritable disease or condition, such that it may be used in gene therapy to treat such disease or condition. Examples of such diseases and conditions include: achromatopsia (ACHM); alpha-1 antitrypsin (AAT) deficiency; Alzheimer’s Disease; aromatic L-amino acid decarboxylase (AADC) deficiency; choroideremia (CHM); cancer; Duchenne muscular dystrophy; dysferlin deficiency; follistatin gene deficiency (BMDSIBM); hemophilia A; hemophilia B; hepatitis A; hepatitis B; hepatitis C; Huntington’s disease; idiopathic Parkinson’s disease; late-infantile neuronal ceroid lipofuscinosis (LINCL, an infantile form of Batten disease); Leber congenital amaurosis (LCA); Leber’s hereditary optic neuropathy (LHON); limb girdle muscular dystrophy IB (LGMD1B); limb girdle muscular dystrophy 1C (LGMD1C); limb girdle muscular dystrophy 2A (LGMD2A); limb girdle muscular dystrophy 2B (LGMD2B); limb girdle muscular dystrophy 21 (LGMD2I); limb girdle muscular dystrophy 2L (LGMD2L); lipoprotein lipase (LPL) deficiency; metachromatic leukodystrophy; neurological disability; neuromotor deficit; neuroskeletal impairment; Parkinson’s disease; rheumatoid arthritis; Sanfilippo A syndrome; spinal muscular atrophy (SMA); X-linked retinoschisis (XLRS); a- sarcoglycan deficiency (LGMD2D); b-sarcoglycan deficiency (LGMD2E); g- sarcoglycan deficiency (LGMD2C) and d-sarcoglycan deficiency (LGMD2F).

IV. Embodiments of the Invention

[0097] The invention concerns a recombinantly-modified adeno-associated virus (AAV) helper vector that comprises an AAV helper function-providing polynucleotide, and uses and compositions thereof. It is particularly directed to the following embodiments E1-E16:

El. A recombinantly-modified adeno-associated virus (AAV) helper vector that comprises an AAV helper function-providing polynucleotide, wherein the polynucleotide comprises a non-native AAV serotype P5 or P40 promoter sequence.

E2. The recombinantly-modified adeno-associated virus (AAV) helper vector of El, wherein the AAV helper function-providing polynucleotide vector comprises a non-native AAV serotype P5 promoter sequence. E3. The recombinantly-modified adeno-associated virus (AAV) helper vector of any one of El or E2, wherein the AAV helper function-providing polynucleotide vector comprises a non-native AAV serotype P40 promoter sequence.

E4. The recombinantly-modified adeno-associated virus (AAV) helper vector of any one of E1-E3, wherein the vector is a plasmid vector.

E5. The recombinantly-modified adeno-associated virus (AAV) helper vector of El, wherein the non-native AAV serotype P5 or P40 promoter sequence replaces a native AAV serotype promoter sequence.

E6. The recombinantly-modified adeno-associated virus (AAV) helper vector of any one of E1-E5, wherein the vector additionally comprises a non-AAV helper functi on-provi ding poly nucl eoti de .

E7. A method for increasing the production titer of a recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV;

(2) the recombinantly-modified adeno-associated virus (AAV) helper vector of E6;

wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

E8. A method for increasing the production titer of a recombinantly-modified adeno-associated virus (rAAV) that comprises a transgene cassette, wherein the method comprises culturing cells that have been transfected with:

(1) the rAAV;

(2) the recombinantly-modified adeno-associated virus (AAV) helper vector of any one of E1-E6; and

(3) an additional vector, especially a plasmid vector, that comprises a non-AAV helper function-providing polynucleotide; wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of the rAAV, and wherein the presence of the non-native AAV serotype P5 or P40 promoter sequence causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the AAV helper function-providing polynucleotide contained native serotype P5 and P40 promoters.

E9. The method of any one of E7-E8, wherein:

(A) the AAV helper function-providing polynucleotide of the vector encodes an AAV1 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(B) the AAV helper function-providing polynucleotide of the vector encodes an AAV2 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(C) the AAV helper function-providing polynucleotide of the vector encodes an AAV3 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(D) the AAV helper function-providing polynucleotide of the vector encodes an AAV4 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(E) the AAV helper function-providing polynucleotide of the vector encodes an AAV5 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes; (F) the AAV helper function-providing polynucleotide of the vector encodes an AAV6 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV7 or AAV8, or a hybrid of one or more of the serotypes;

(G) the AAV helper function-providing polynucleotide of the vector encodes an AAV7 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV8, or a hybrid of one or more of the serotypes; or

(H) the AAV helper function-providing polynucleotide of the vector encodes an AAV8 Cap protein, and the non-native AAV serotype promoter sequence is a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7, or a hybrid of one or more of the serotypes.

E10. The method of any one of E7-E9, wherein the cells are human embryonic kidney cells, baby hamster kidney cells or sf9 insect cells.

Ell. The method of E10, wherein the cells are HEK293 human embryonic kidney cells.

E12. The method of E10, wherein the cells are BHK21 baby hamster kidney cells.

E13. The method of any one of E7-E12, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition.

E14. A preparation of the recombinantly-modified adeno-associated virus (rAAV) produced by the method of E13.

E15. A pharmaceutical composition that comprises the recombinantly-modified adeno-associated virus (rAAV) produced by the method of E13, and a pharmaceutically acceptable carrier.

E16. The preparation of recombinantly-modified adeno-associated virus (rAAV) of E14, or the pharmaceutical composition of E15, for use in the treatment of the genetic or heritable disease or condition. EXAMPLES

[0098] Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.

Example 1

Comparison Of rAAV Production Titers By Cells Transfected With AAV RC2

Helper Plasmid Vectors Having A Non-Native AAV Serotype

P5 Promoter Sequence

[0099] In order to demonstrate the ability of non-native AAV serotype promoter sequences to affect the production titer of rAAV, derivatives of AAV helper plasmid AAV RC2 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV2 serotype) were constructed that comprised a non-native AAV serotype promoter sequence (Figure 11) in lieu of the native AAV2 serotype P5 promoter of such plasmid (Figure 12A; downward striped rectangle). The P19 and P40 promoters of the constructs were not changed, and thus were both native AAV2 serotype promoter sequences (Figure 12A; solid black rectangles).

[00100] The following constructs were employed; the sequences of the promoter regions are shown in Table 1:

(1) Parent-RC2 - pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep gene and a partial portion of the full AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV2 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(2) P5(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 1 (SEQ ID NO:9);

(3) P5(2)-RC2 - a derivative of plasmid vector pAAV-RC2 in which the partial AAV2 serotype P5 promoter sequences of Parent-RC2 had been replaced with the full-length P5 promoter sequences of AAV serotype 2 (SEQ ID NO: 10);

(4) P5(3)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 3 (SEQ ID NO: 11); (5) P5(4)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 4 (SEQ ID NO: 12);

(6) P5(5)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 5 (SEQ ID NO: 13);

(7) P5(6)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 6 (SEQ ID NO: 14);

(8) P5(7)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 7 (SEQ ID NO: 15); and

(9) P5(8)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequences of AAV serotype 8 (SEQ ID NO: 16).

[00101] Figure 12B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. The production titers of rAAV were obtained using a triple plasmid transfection system with an rAAV (pGOI; BBa_K404119), and an Ad helper plasmid (pHelper) that provided the required adenoviral functions. Plasmid pGOI is an rAAV plasmid vector that comprises, in the 5’ to 3’ direction, a 5’ ITR, a CMV promoter, a b-globin intron, a polynucleotide encoding the yellow fluorescent protein mVenus (Nagai, T. et al. (2002)“ A Variant Of Yellow Fluorescent Protein With Fast And Efficient Maturation For Cell-Biological Applications ,” Nat. Biotechnol. 20(1):87- 90), the polyA domain of human growth hormone and a 3’ ITR. Figure 12B reveals that the serotype of the P5 promoter affects rAAV production titers, and indicates that replacing the native AAV2 P5 promoter of the plasmid vector pAAV-RC2 with an AAV5 serotype P5 promoter greatly decreased rAAV production titer, whereas replacing the native AAV2 P5 promoter of the plasmid vector pAAV-RC2 with a P5 promoter of AAV serotype 1, 3, 5, 7 or 8 greatly increased rAAV production titer. Example 2

Comparison Of rAAV Production Titers By Cells Transfected With AAV RC2

Helper Plasmid Vectors Having A Non-Native AAV Serotype

P40 Promoter Sequence

[00102] In order to further demonstrate the ability of non-native AAV serotype promoter sequences to affect the production titer of rAAV, derivatives of AAV helper plasmid AAV RC2 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV2 serotype) were constructed that comprised a non-native AAV serotype promoter sequence (Figure 11) in lieu of the native serotype P40 promoter of such plasmid (Figure 13A; upward striped rectangle). The P5 and P19 promoters of the constructs were not changed, and thus were both native AAV2 serotype promoter sequences (Figure 13A; solid black rectangles).

[00103] The following constructs were employed; the sequences of the promoter regions are shown in Table 1:

(1) Parent-RC2 - pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep gene and a partial portion of the full AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV2 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(2) P40(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 1 (SEQ ID NO: 17);

(3) P40(2)-RC2 - a derivative of plasmid vector pAAV-RC2 in which the AAV2 serotype P40 promoter sequences of Parent-RC2 had been replaced with the P40 promoter sequences of AAV serotype 2 (SEQ ID NO: 18);

(4) P40(3)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 3 (SEQ ID NO: 19);

(5) P40(4)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 4 (SEQ ID NO:20);

(6) P40(5)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 5 (SEQ ID NO:21); (7) P40(6)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 6 (SEQ ID NO:22);

(8) P40(7)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 7 (SEQ ID NO:23); and

(9) P40(8)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequences of AAV serotype 8 (SEQ ID NO:24).

[00104] Figure 13B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. Production titers of rAAV were obtained essentially as described in Example 1. The results of the investigation reveal that the serotype of the P40 promoter also affects rAAV production titers, and indicate that replacing the native AAV2 P40 promoter of the plasmid vector pAAV-RC2 with an AAV5 serotype P40 promoter greatly decreased rAAV production titer, whereas replacing the native AAV2 P40 promoter of the plasmid vector pAAV-RC2 with an AAV1 serotype P40 promoter or with an AAV8 serotype P40 promoter greatly increased rAAV production titer.

Example 3

Comparison Of rAAV Production Titers By Cells Transfected With AAV RC2

Helper Plasmid Vectors Having Non-Native AAV Serotype

P5 and P40 Promoter Sequences

[00105] In order to further demonstrate the ability of non-native AAV serotype promoter sequences to affect the production titer of rAAV, derivatives of AAV helper plasmid AAV RC2 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV2 serotype) were constructed that comprised non-native AAV serotype promoter sequences (Figure 11) in lieu of the native AAV2 serotype P5 (Figure 14A; downward striped rectangle) and P40 (Figure 14A; upward striped rectangle) promoters of such plasmid. The AAV2 P19 promoter of the constructs were not changed, and thus was the native AAV2 serotype promoter sequence (Figure 14A; solid black rectangle). [00106] The following constructs were employed; the sequences of the promoter regions are shown in Table 1:

(1) Parent-RC2 - pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep gene and a partial portion of the full AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV2 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(2) P5(2)-RC2 - a derivative of plasmid vector pAAV-RC2 in which the partial AAV2 serotype P5 promoter sequences of Parent-RC2 had been replaced with the full-length P5 promoter sequences of AAV serotype 2 (SEQ ID NO: 10);

(3) P5(3)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV3 (SEQ ID NO: 11);

(4) P5(5)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV5 (SEQ ID NO: 13);

(5) P40(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter sequences had been replaced with the P40 promoter sequence of AAV1 (SEQ ID NO: 17);

(6) P5(2)/P40(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV2 (SEQ ID NO:10) and in which native P40 promoter sequences had been replaced with the P40 promoter sequence of AAV1 (SEQ ID NO: 17);

(7) P5(3)/P40(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV3 (SEQ ID NO: 11) and in which native P40 promoter sequences had been replaced with the P40 promoter sequence of AAV1 (SEQ ID NO: 17); and

(8) P5(5)/P40(1)-RC2 - a derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV5 (SEQ ID NO: 13) and in which native P40 promoter sequences had been replaced with the P40 promoter sequence of AAV1 (SEQ ID NO: 17) [00107] Production titers of rAAV were obtained essentially as described in Example 1. Figure 14B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. As shown in Figure 14B, the replacement of the native P5 and P40 promoters of pAAV-RC2 with the P5 promoter sequence of AAV3 or AAV5 and the P40 promoter sequence of AAV1 synergistically increased rAAV production titers.

Example 4

Comparison Of rAAV Production Titers By Cells Transfected With AAV RC6

Helper Plasmid Vectors Having Non-Native AAV Serotype

P5 and P40 Promoter Sequences

[00108] In order to further demonstrate the ability of non-native AAV serotype promoter sequences to affect the production titer of rAAV, derivatives of AAV helper plasmid AAV RC6 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV6 serotype) were constructed that comprised non-native AAV serotype promoter sequences (Figure 11) in lieu of the native AAV2 serotype P5 (Figure 15A; downward striped rectangle) and P40 (Figure 15A; downward striped rectangle) promoters of such plasmid. The AAV2 P19 promoter of the constructs were not changed, and thus was the native AAV2 serotype promoter sequence (Figure 15A; solid black rectangle).

[00109] The following constructions were employed; the sequences of the promoter regions are shown in Table 1:

(1) Parent-RC6 - pAAV-RC6 (SEQ ID NO:4), which contains the AAV2 rep gene and its native AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV6 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(2) P5(1)-RC6 - a derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV1 (SEQ ID NO:9);

(3) P5(2)-RC6 - a derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV2 (SEQ ID NO: 10); (4) P5(3)-RC6 - a derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV3 (SEQ ID NO: 11);

(5) P5(7)-RC6 - a derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV7 (SEQ ID NO: 15); and

(6) P5(8)-RC6 - a derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV8 (SEQ ID NO: 16).

[00110] Figure 15B shows the production titers of rAAV obtained using such AAV helper plasmid vectors. Production titers of rAAV were obtained essentially as described in Example 1.

[00111] The results of the investigation are shown in Figures 15B and 15C, and reveal that the production titers of rAAV obtained using such AAV helper plasmid vectors. As shown in such Figures, the replacement of the native P5 and P40 promoters of pAAV-RC6 with the P5 promoter sequence of AAV serotype 1, 2, 3, 7 or 8 increased rAAV production titers.

Example 5

Comparison Of rAAV Production Titers By Cells Transfected With AAV RC1, AAV RC5 or AAV RC7 Helper Plasmid Vectors Having Non-Native AAV

Serotype P5 and P40 Promoter Sequences

[00112] In order to further demonstrate the ability of non-native AAV serotype promoter sequences to affect the production titer of rAAV, derivatives of AAV helper plasmid AAV RC1 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV1 serotype), derivatives of AAV helper plasmid AAV RC5 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV5 serotype) and derivatives of AAV helper plasmid AAV RC7 (having an AAV2 rep gene and a cap gene that encodes Cap protein of the AAV7 serotype) were constructed that comprised non-native AAV serotype promoter sequences (Figure 11) in lieu of the native AAV2 serotype P5 (Figure 16A; downward striped rectangle) and/or P40 (Figure 16A; upward striped rectangle) promoter sequences of such plasmids. [00113] The following constructions were employed; the sequences of the promoter regions are shown in Table 1:

(1) Parent-RCl - pAAV-RCl (SEQ ID NO:l), which contains the AAV2 rep gene and its native AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV1 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(2) Parent-RC5 - pAAV-RC5 (SEQ ID NO:3), which contains the AAV2 rep gene and its native AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV5 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(3) Parent-RC7 - pAAV-RC7 (SEQ ID NO:5), which contains the AAV2 rep gene and its native AAV2 serotype P5 promoter sequence (SEQ ID NO: 10), and the AAV7 cap gene, whose expression is controlled by a native AAV2 P40 promoter sequence (SEQ ID NO: 18);

(4) P5(2)-RC1 - a derivative of plasmid vector pAAV-RCl in which native AAV 1 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV2 (SEQ ID NO: 10);

(5) P5(7)-RC1 - a derivative of plasmid vector pAAV-RCl in which native AAV 1 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV7 (SEQ ID NO: 15);

(6) P5(8)-RC1 - a derivative of plasmid vector pAAV-RCl in which native AAV 1 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV8 (SEQ ID NO: 16);

(7) P5(7)-RC5 - a derivative of plasmid vector pAAV-RC5 in which native AAV5 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV7 (SEQ ID NO: 15);

(8) P5(2)-RC7 - a derivative of plasmid vector pAAV-RC7 in which native AAV7 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV2 (SEQ ID NO: 10).

(9) P5(7)-RC7 - a derivative of plasmid vector pAAV-RC7 in which native AAV7 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV7 (SEQ ID NO: 15); and (10) P5(8)-RC7 - a derivative of plasmid vector pAAV-RC7 in which native AAV7 serotype P5 promoter sequences had been replaced with the P5 promoter sequence of AAV8 (SEQ ID NO: 16).

[00114] Production titers of rAAV were obtained essentially as described in Example 1. The results of the investigation are shown in Figure 16B, and reveals that the replacement of the native P5 promoter sequences of pAAV-RCl, pAAV-RC5, and pAAV-RC7 with P5 promoter sequence of AAV serotype 2, 7 or 8 increased rAAV production titers.

[00115] All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.